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Abstract

HUMAN PAPILLOMAVIRUS: IDENTIFYING VACCINATION RATES, BARRIERS, AND
INFORMATION GATHERING AMONG COLLEGE WOMEN AGES 18-26

By Timmerie Fay Cohen, Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree Doctor of
Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2013

Major Director: Janet R. Hutchinson PhD
Chairman Gender Sexuality and Women’s Studies
L. Douglas Wilder School of Government and Public Affairs

This dissertation examines vaccination rates for Human Papillomavirus (HPV) among
college women 18-26 years of age who participated in the American College Health
Association’s National College Assessment (ACHA-NCHA). Utilizing secondary data, this
research sought to report HPV vaccination rates among a racially diverse population and to
identify potential barriers to vaccination.
The ACHA-NCHA survey provided a large sample size (N=68,193) in which to perform
a binary logistic regression analysis. Demographic characteristics were analyzed as potential
barriers to HPV vaccination. Additionally, lack of certain health behaviors were explored as
potential barriers to HPV vaccination.

xi

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

In this study, White/non-Hispanic women had a higher HPV vaccination rate when
compared to minority women. The binary regression analysis demonstrated that minority women
were less likely to receive the HPV vaccine. Furthermore, it was determined that as the age of
the respondents increased, the likelihood of receiving the vaccine decreased. Health behaviors
that were predictive of receiving the HPV vaccine included receiving the Hepatitis B and
Influenza vaccine, number of sexual partners and receiving sexually transmitted disease
information. Women who received a gynecological exam were almost twice as likely to receive
the vaccine, as were women who had parental health insurance coverage.
One aim of The Affordable Care Act (2010) is to decrease disparities in health care.
Drawing attention to potential barriers to HPV vaccination allows policy makers to make
informed decisions regarding future activities to reduce disparities. Health promotion activities
should be targeted to specific populations in an effort to increase HPV vaccination rates.

xii

Chapter 1
Introduction
Statement of Problem
The introduction of a new vaccine does not end with Federal Drug Administration (FDA)
approval and recommendation from the Centers for Disease Control and Prevention (CDC).
Scientific acceptance is not enough, barriers to vaccination exist. Increasing voluntary
vaccination rates is a complex process for which there is no simple solution. Immunization
strategies to reach targeted populations, those who benefit from the vaccine, include strategic
planning by public health officials, healthcare organizations, healthcare providers, advocates, and
other stakeholders. Research is imperative to gain an understanding of the barriers to
vaccination adoption. The United States has an increasingly diverse population. Gender, race,
age, socioeconomic status, education and healthcare utilization patterns are some of the factors
shown in the literature to influence vaccination uptake.
The purpose of this research is to describe Human Papillomavirus (HPV) vaccination
rates and possible barriers to HPV vaccination among college women ages 18-26. The
American College Health Association’s National College Health Assessment (NCHAII) survey
provided this analysis with a large sample (N=68,193) of college women to extend the body of
knowledge concerning HPV vaccination rates.
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Introduction
The Human Papillomavirus (HPV) is the most common sexually transmitted disease in
the United States and has been strongly linked to cervical cancer. More than 100 types of HPV
have been identified. However, types 16 (HPV-16) and 18 (HPV-18) are responsible for up to
98% of all cervical cancers, and types 6 and 11 are associated with genital warts (Schiffman, et
al., 2007, Walboomers, 1999). According to the Centers for Disease Control and Prevention
(CDC), 50% of the reproductive-age population in the United States has been infected with HPV.
Although this would appear to be a staggering figure, many of the HPV types are asymptomatic
and do not lead to non-invasive or invasive carcinomas. Following the natural history of HPV
has proved difficult since the virus can be transient (Goldie, et al., 2003, Schiffman, et al., 2007).
Age-specific models of HPV infection and development of cancerous lesions would benefit
health policy makers, but conclusive models remain elusive due to the transient nature of the
virus.
Approximately 12,000 women are diagnosed with cervical cancer annually and 4,000 of
those women will die (NCI, Cervical Cancer Fact Sheet, 2012). Cervical cancer comprises 20%
of gynecologic cancers in the United States. The average age of onset of cervical cancer is 45 to
55 years; black, Hispanic, and Native American women are at increased risk of developing
cervical cancer compared to Caucasian women (CDC, Cervical Cancer Fact Sheet, 2012). The
populations at greatest risk for HPV infection are men and women aged 20-24 (CDC, Cervical
Cancer Fact Sheet, 2012, Schiffman, et al., 2007). Globally, annual cervical cancer rates are
much higher, with 500,000 confirmed cases and 275,000 deaths (WHO, Global Cancer Statistics,
2010). Due to the incidence of cervical cancer, women suffer disproportionately from HPV, but
men and women can both harbor and transmit HPV.
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For decades, Papanicolaou testing (the Pap smear) was the physician’s principal tool for
the early detection of cervical cancer. The Pap smear is performed to screen for pre-invasive
cervical lesions and invasive cervical malignancies and thus prevent cervical cancer in sexually
active women. It has been a highly effective test: since the 1950s the cervical cancer rate in the
United States has decreased 80% due to Pap smear testing. Until 2012, Pap smear testing was
recommended yearly for women who were sexually active or over the age of 18; however,
recommendations have changed to start Pap testing at the age of 21, or three years after initiating
intercourse. Yearly screening has been replaced with the recommendation that women with
negative Pap results and those who are under 30 receive Pap testing every three years. The new
recommendation for average risk women 30-65 is to receive Pap testing every 3-5 years. Any
positive Pap test in the past calls for yearly testing. The CDC has published current 2012
screening guidelines for average-risk women (See Appendix A).
Still, as the cervical cancer rates cited above show, it is not prevented in thousands of
women. In June 2006, physicians gained a valuable addition to their toolbox. The first vaccine to
prevent HPV infection was approved by the United States Food and Drug Administration (FDA)
for use in girls and young women, ages 9 to 26. The vaccine was also deemed safe for males
(Markowitz et al., 2007, National Cancer Institute, Cervical Cancer Fact Sheet, 2012). It
provides nearly 100% protection against HPV types 16 and 18, thus greatly reducing the
likelihood of developing cervical cancer by 75%. The vaccine is given in a series of three
intramuscular shots over a 6-month period at an average cost of $320.00. The current
recommendation is that females and males get the vaccine between the ages of 11-12 or before
first sexual contact. This ensures that the vaccine offers the most benefit (CDC, Cervical Cancer
Fact Sheet, 2012).
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At first glance, one would assume that a vaccine that prevents cancer would be widely
endorsed by physicians and sought after by patients. However, controversy surrounds this
vaccine. Public health policymakers have encountered determined resistance to the vaccine from
some parents, either because of general concerns about vaccine safety or specific objections to
this vaccine because of its perceived connection with sexual activity. One concern is “that
vaccination against a sexually transmitted disease would increase sexual activity in young girls
and unmarried women” although no data supports this assertion (Balong, 2009, Colgrove, 2006,
National Conference of State Legislatures, HPV vaccination, 2012). It is argued by some that
there is a moral justification for compulsory HPV vaccination. The public health standpoint is
that vaccinations are used to reduce harm to individuals, and the HPV vaccine does that by
protecting against a common virus (Balong, 2009, Zimmerman, 2006).
Literature review summary
Increasing the rate of the HPV vaccination has been of interest to public health authorities
and non-governmental organizations since the vaccine was approved by the FDA and
recommended by agencies such as the CDC. Vaccination of adolescent females, ages 11-12,
before they enter middle school was mandated by Virginia and the District of Columbia, with an
option for parents to opt out of the requirement. Twenty-two states have had legislation
introduced to mandate vaccination for girls entering middle school, but all such bills were either
withdrawn or sent to committee without further action. New Mexico passed legislation that was
later vetoed by the governor. In 2007, the Governor of Texas mandated vaccination for HPV;
however, the executive order was rescinded by the state House and Senate (National Conference
of State Legislatures, HPV vaccination, 2013). This widespread lag in policy action by states
means that even if they mandate in the future that middle school girls be vaccinated for HPV,
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there will be a large catch-up group of females aged 18-26 that may suffer disproportionately
from HPV infection. The American Public Health Association (2009) reported that only 41% of
female undergraduate students surveyed were vaccinated for HPV. This prevalent sexually
transmitted disease is not only responsible for cervical cancer in women, but also 40% of vaginal
cancers and vulvar cancers. In men, HPV is linked to 90% of anal cancers and penile cancers
and 12% of oropharyngeal cancers (Kim, et al., 2008, National Cancer Institute, Cervical Cancer
Fact Sheet, 2012). Both men and women, therefore, could realize significant benefit from the
HPV vaccination.
For women who already have had sexual intercourse, some studies suggest that the
vaccine could offer some protection (Adams, et al., 2009, Castellsague, et al., 2011, Harper, et
al., 2004). The CDC supports vaccination in women up to the age of 26 which may be beneficial
where there is no prior exposure to the virus, when there is transient virus, or when it can provide
protection from non-present HPV strains (Adams, et al., 2009, Castellsague, et al., 2011, Harper,
et al., 2004). While vaccination in women over the age of 17 is supported by federal agencies,
realizing an increase in vaccination rates is not solely dependent on recommendation.
The Health Belief Model (HBM) is a cognition model often used in explaining and
predicting health behaviors. The constructs of the model are perceived susceptibility, perceived
severity, perceived barriers and benefits, and cues to action (Becker, 1974). Applied to the public
health policy implications of HPV transmission and its prevention, through education and
vaccination, the HBM can shed light on current knowledge deficits and predict useful avenues of
research to explore.
Research has shown that women are unlikely to believe they are susceptible to HPV,
even though it is the most common sexually transmitted disease (McAlearney, et al., 2010,
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Nadarzynski, et al., 2012). In one study that used the HBM framework, 80% of women believed
that they were not at risk from STD’s when in reality they were. Even though 99% of women
believed that STD’s and cancer are serious, only 16% believed that they were at risk for the
development of cervical cancer (Burak, et al., 1997). Providing information clearly explaining
the link between HPV and cervical cancer along with infection risk is important when
undertaking educational efforts (Nadarzynski, et al., 2012).
Knowledge of the HPV virus and its negative repercussion is not uniformly pervasive
among adult women (Baer, et al., 2000, D’Urso, et al., 2007, Gerend, et al., 2008, Giede, et al.,
2010, Kahn, et al., 2007 Philips, et al., 2003). College students are a high-risk group for
contracting and spreading HPV, yet most students do not believe they are at risk (Ramirez, et al.,
1997, Zimet, et al., 2006, Yacobi, et al., 1999). Race is also considered a barrier to vaccination;
in one study blacks were less likely to receive the HPV vaccine (Bendik, et al., 2011).
Identifying information-gathering behavior and vaccination rates in college age women can
guide the best allocation of resources to be used in educating women aged 18-26 about this virus
and its repercussions. While knowledge of HPV and its link to the development of cancer has
increased since the development of the vaccine, HPV remains a major concern.
Barriers to HPV vaccination include deficiency in knowledge about the virus and
prevention of its related diseases. The lack of knowledge that the virus is responsible for the
development of cancer and genital warts, but it also applies to the knowledge deficits concerning
the cost of the three-shot series of the vaccine, the misperceptions of vaccine safety, and vaccine
effectiveness in general (Blumenthal, et al., 2008, Brewer, et al., 2007, Jones, et al., 2008,
Rosenthal, et al., 2011). Studies have shown a physician recommendation increases the
likelihood that women will seek the HPV vaccine (Brewer, et al., 2007, Giambi, et al., 2011,
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Rosenthal, et al., 2011). Cermak, et al., reported that women said their physicians were not
providing them with information regarding HPV and its link to cancer. The survey included 109
professional women of whom 71.6% reported that their physicians did not discuss HPV with
them. In addition, all the women in this study had a gynecological exam within 18 months
(Cermak, et al., 2010).
Women receive information regarding HPV and its negative consequences by physician
patient education, media, printed materials, and parent and peer education. There is
inconsistency in the knowledge gained by women (Hall, et al., 2008). Content analysis of media
sources showed that misleading and missing information abounds regarding HPV (Ache, et al.,
2008, Hall, et al., 2008, Kelly, et al., 2009). Also, physician to patient education tends to be
inconsistent (Cermak, et al., 2010, Kahn, et al., 2007). Accurate, non-judgmental education
could provide women with the information needed to make an informed decision regarding
vaccination (Kahn, et al, 2007).
The cost of the vaccine to the patient was also shown to be a barrier. Women of lower
socioeconomic status with no insurance coverage were less likely to receive the HPV vaccine
(Kahn, et al., 2008). In addition to a lack of knowledge concerning HPV, vaccine safety, costs,
and future toxicity are barriers to vaccination (American Public Health Association, Adult
Vaccine Coverage, 2010).
The intent of adult women to receive the HPV vaccine is linked to greater perceived risk
of infection, multiple sexual partners, having a close friend or relative with a HPV linked illness,
and greater knowledge of the virus (Jones, et al., 2008). Intent to receive the HPV vaccination
has also been linked to an increase in sexual partners (Bendik, et al., 2011, Jones, et al., 2008,
Kahn, et al., 2003). Physician recommendation increases intention to receive the vaccination
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series (Brewer, et al., 2007, Giambi, et al., 2011, Rosenthal, et al., 2011). Voluntary
vaccinations, such as the influenza vaccine, are often dependent on society’s common concerns,
perceptions of vaccine safety, perceptions of personal risk, and side effects (Poland, 2010).
Voluntary HPV vaccination may share these same obstacles.
Policy Considerations
Increasing the HPV vaccination rate among women ages 18-26 may rely on multiple
interventions, but more data is needed. Obtaining a more complete representation of this catchup group (women between the ages 18-26) would provide insight into their demographics and
vaccination rates. Approximately 12,000 women are diagnosed with cervical cancer in the
United States annually (CDC, Cervical Cancer Fact Sheet, 2012). Along with Pap smear
screening, the HPV vaccine clearly could decrease the incidence of future cervical cancer in
women currently 18-26 years old. Factors that influence vaccination rates, such as STD
information-gathering behavior, number of sexual partners, and multiple demographic variables
can be investigated by using a large national database that includes questions regarding HPV
vaccination. Policy makers will be exploring strategies and implementing programs under the
Affordable Care Act (2010) that expand preventive services in community and clinical settings
which will hopefully decreasing disparities in health care. The medical home model,
coordinated and complete, medical care is currently being explored as an avenue to increase
quality comprehensive care (Patient Centered Homes, Health Affairs, 2010). Research
addressing barriers to preventive care may be of use when crafting strategies in increase HPV
vaccination rates.
Policies concerning promotion of HPV vaccination in specific age groups, including
college age women, could result in prevention monies being spent in a targeted manner.
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Predicting the long term effectiveness of the vaccine, whether a vaccine booster will be needed,
for instance, is still debatable; this adds to the deficiencies of a solely cost/benefit analysis
(Goldie, et al., 2003). Increasing HPV vaccination and continued cervical cancer screening with
Pap smears could lead to decreased mortality due to cervical cancer (Dempsey, et al., 2008,
Goldie, et al., 2003,). Gathering mortality rates in currently vaccinated adolescents and women
in the “catch-up” group could take a decade or more.
Exploring barriers to HPV vaccination can aid policy makers in making more informed
decisions about how health promotion monies are to be spent and/or vaccination programs are to
be implemented. Medicare and Medicaid as well as most private insurances cover the cost of the
vaccine series. Despite this, barriers to vaccination exist. The average knowledge of HPV is still
considered low among college age women (Hall, et al., 2008, Lenselink, et al., 2008, Philips, et
al., 2003).
Current studies point to a general lack of knowledge regarding HPV, but these previous
studies are concentrated in single-institution student or limited populations. There is limited
research into the success rates of programs that use education to increase HPV vaccination rates
in college women. The greatest benefit for women is to receive HPV vaccinations before their
first sexual encounter. However, without targeting specific barriers and increasing vaccination
rates, no benefit will be realized. Policy makers may need direction when making decisions
regarding HPV vaccination in the “catch-up” group due to their specific barriers. The goal of
this study is to illuminate some potential barriers to HPV vaccination in college age women.
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Methods
This summary contains the research problem, research question, research design, and population
of interest, source of data, survey instrument, dependent and independent variables, and method
of analyses.
Research Problem
The HPV vaccine has the potential to further decrease the development of cervical cancer
in women between the ages of 18-26. This group of women may suffer disproportionately from
cervical cancer compared to adolescent girls who received the vaccine. For health policy makers
there is a need to identify potential barriers, including demographic barriers, to vaccination if
increased HPV vaccination in women age 18-26 is desired.
Research Question
Within the parameters of data from the American College Health Association-National College
Health Assessment, what factors can be identified that affect HPV vaccination rates in college
women 18-26 years old?
Null Hypotheses
1. H0: There is no difference in demographic characteristics between women who receive
the HPV vaccine and those who do not.
2. H0: There is no difference in HPV vaccination rates between college women who receive
information regarding STDs and those who do not.
3. H0: There is no difference in HPV vaccination rates in college women who receive yearly
gynecological exams and those who do not.
4. H0: There is no difference in HPV vaccination rates among college women who receive
the Hepatitis B vaccine(s) and those who do not.
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5. H0: There is no difference in HPV vaccination rates among college women who receive
the influenza vaccine and those who do not.
6. H0: There is no difference in HPV vaccination rates of college women who have
insurance and those who do not.
7. H0: There is no difference in HPV vaccination rates in women who have multiple sexual
partners and those who do not.
8. H0: There is no difference in the likelihood of HPV vaccination amongst the predictor
variables in the binary logistic regression.
Available data to be analyzed
A secondary analysis of the American College Health Association (ACHA) National College
Health Assessment (NCHAII) will be conducted, with emphasis on questions dealing with
demographics, HPV vaccination, STD information gathering, gynecological exams, Hepatitis B
and influenza vaccination rates, and sexual behavior. The sample size for the analysis is 68,193.
The National College Health Assessment (NCHA), designed and distributed by the American
College Health Association, is a national survey that has been used by 587 higher education
institutions as of fall 2011. This comprehensive survey includes questions that track health
issues and safety trends. Alcohol, tobacco, and drug use and frequency, sexual health, weight
issues, nutrition and exercise habits, mental health issues, personal safety, and preventive health
are among the research questions focused on by the survey. This survey was first conducted in
28 institutions in the spring of 2000. A revised survey was used in 2008 that includes a question
asking whether respondents have received the HPV vaccine, and that revised survey is currently
in distribution. This survey provides a large sample of women with mixed demographic
characteristics, and extensive demographic information, such as age, race, insurance status, years
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of higher education, grade point average, is collected. Information and survey questions
regarding sexual behaviors, receiving information regarding STD’s, gynecological exam history,
and vaccination history (including the HPV vaccination), and a question regarding health
insurance status, could all be used in statistical analysis. Using logistic regression to establish
what variables influence HPV vaccination rates can discern and identify potential barriers to
HPV vaccination.
For the NCHA, students at each institution are randomly selected by classrooms. All
surveys are anonymous or confidential; no identifiable information is collected. The survey
takes an average of 30 minutes to complete and the depth of the survey is extensive. The survey
can be paper-based or web-based. General demographic and health questions, including
vaccinations, along with a wide range of questions that assess the student’s alcohol, tobacco, and
drug use, sexual health and safety, weight management and nutrition, violent encounters and
personal safety, and mental health, are asked in a scaled format. All surveys are kept
confidential; the descriptive data is given to each educational institution, and data is compiled by
the American College Health Association to obtain descriptive statistics for all participating.
The surveyors acknowledge that the information is not to be generalized to all universities since
universities are self-selected. This survey is administered once a year at the participating
institutions in the fall or the spring semester based on the colleges’ preference. The survey’s
reliability and validity were evaluated through a series of comparisons and statistical analysis
based on past surveys, such as the Harvard School of Public Health’s 1999 Alcohol Study and
the CDC’s National College Health Risk Behavior Survey. The outcomes of those evaluations
were published by the American College Health Association (2013).
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The National College Health Assessment II (NCHAII) was a revision of the previous
survey that had collected 832 institutional data sets from 2000 through the spring of 2008. The
survey was revised, in the fall of 2008, to include questions on HPV, the flu vaccine, and mental
health. Since fall 2008, 565 institutional data sets have been collected.

The secondary data

analysis for this research will use the data from 2008 (fall), 2009 (spring and fall), and 2010
(fall), 253 institutions contributed. The data sets from spring 2010 and years 2011 and 2012 are
not available for use in outside research. This study will be selective with the questions used in
the secondary data analysis; questions directly and indirectly related to HPV will be the focus of
the analysis.
Along with descriptive statistics, correlation analysis, and binary logistic regression was
employed, the dependent variable being HPV vaccination, which was dichotomous. Descriptive
statistics and chi-square tests were employed to explore associations between the dependent and
the independent variables: race, geographic location, receiving STD information, having a
gynecological exam in the past 12 months, receiving the Hepatitis B and influenza vaccine, and
primary source of health insurance. Independent variables used in the binary logistic analysis
were: race, geographic location, receiving STD information, having a gynecological exam in the
past 12 months, receiving Hepatitis B, receiving influenza vaccine, and primary source of health
insurance, age, and number of sexual partners in the past 12 months. The following variables
were reported by race and geographic location: HPV vaccination, receiving STD information
from the respondents’ college/university, having a gynecological exam in the last 12 months, and
source of health insurance.
Binary logistic regression was an appropriate statistical tool for this analysis since the
dependent variable; HPV vaccination was dichotomous (yes/no). The following independent
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variables were categorical: race, geographic location, receiving STD information from the
respondents’ college/university, having a gynecological exam in the past 12 months, receiving
Hepatitis B vaccination, receiving influenza vaccination, and primary source of insurance.
Continuous independent variables include age and number of sexual partners. IBM SPSS
Statistic 20 computer software was used to complete the data analysis.
Summary of findings
It was demonstrated that White/non-Hispanic women had a higher rate of HPV
vaccination compared to minorities (Black/non-Hispanic, Hispanic/Latino, Asian/Pacific
Islander, American Indian/Alaskan Native/Native Hawaiian, and “other”). The racial category
Biracial/Multiracial was not significant in the binary logistic regression, most likely due to the
small sample size. HPV vaccination rates within racial categories are shown in Figure 1.1.

Figure 1.1 Percentages of women who received the HPV vaccine within racial categories

51%
44%

47%

46%
40%

White/non-Hispanic
38%

Black/non-Hispanic
Hispanic/Latino
Asian/Pacific Islander
American Indian/Alasken
Native/Native Hawaiian
other

% Within race that received the HPV vaccine
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The binary logistic regression showed that minority women (Black/non-Hispanic,
Hispanic/Latino, Asian/Pacific Islanders, American Indian/Alaskan Natives/Native Hawaiians,
and “other”) had a decreased likelihood of receiving the HPV vaccine compared to White/nonHispanic women (p=.000). Table 1.1 demonstrates the odds-ratios and 95% confidence intervals
of statistically significant minority categories when compared to White/non-Hispanic women.

Table 1.2 Odds-ratios and 95% confidence intervals of racial categories that were statistically significant
in the binary logistic regression
95% CI

Odds-ratio Lower

Upper

White/non-Hispanic (ref)*

1

Black/non-Hispanic

0.744

0.692

0.801

Hispanic/Latino

0.903

0.840

0.971

Asian/Pacific Islander

0.795

0.746

0.847

American Indian/Alaskan
Native/Native Hawaiian
Other

0.852

0.730

0.995

0.642

0.551

0.748

*Reference group (ref)

White/non-Hispanic women had the highest rate of receiving a gynecological exam in the
past twelve months (58). Black/non-Hispanic women and American Indian/Alaskan
Native/Native Hawaiian had gynecological exam rates of 53% and 54%, respectively.
Hispanic/Latino had a gynecological exam rate of 44% while the racial category with the lowest
gynecological exam rate, 28%, was seen in Asian/Pacific Islanders. Fifty five percent of women
who received a gynecological exam in the past 12 months also received the HPV vaccine and
43% of women who did not receive a gynecological exam received the HPV vaccine.
15

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Furthermore, it was shown in the binary logistic regression that receiving a gynecological exam
in the past 12 months increased the likelihood of receiving the HPV vaccine by nearly two fold
(OR=1.939, 95% CI=1.868-2.007).
In addition, the binary logistic regression demonstrated that receiving the Hepatitis B and
influenza vaccines were statistically significant (p=.000) for increasing the likelihood of
receiving the HPV vaccine (OR=4.1, 95% CI=3.796-4.428 and OR=2.55, 95% CI=2.465-2.643
respectively). White/non-Hispanic women received the Hepatitis B vaccine at a rate of 93%,
which is the highest percentage within the racial categories. Asian/Pacific Islanders’ had the
lowest rate (85%) of receiving the Hepatitis B vaccine. It was expected that Hepatitis B
vaccination rates would be high, since it is commonly a requirement for college matriculation.
Influenza vaccination rates were considerably lower since it is voluntary to receive the vaccine.
In fact, only 37% (Range 36% -38%) of the women in this study received vaccination for
influenza. It is interesting to note that 64% of women who received the influenza vaccine also
received the HPV vaccine.
Source of health insurance (college/university plan, parents’ plan, another plan, and no
insurance) was statistically significant in the binary regression model (p=.001) when predicting
HPV vaccination. It was determined that 28% of students in the analysis were lacking a source
of health insurance. Seventy-two percent of women reported having a source of health
insurance, with the majority of these women (75%) being covered by their parents’ insurance.
Comparing HPV vaccination rates and source of health insurance, it was shown that 54% of
women who were covered by their parents’ insurance received the HPV vaccine. Conversely,
only 28% of women who had no health insurance received the vaccine. The binary logistic
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regression demonstrated that having parental insurance coverage increased the likelihood of
receiving the HPV vaccine by nearly two fold (OR=1.845, 95% CI=1.689-2.016).
Age and number of sexual partners were also statistically significant in the binary
regression model (p=.000). As age increased, the likelihood of receiving the HPV vaccine
decreased, which is most likely due to the fact that women over the age of 19 may not have been
exposed to HPV vaccination recommendations as adolescents. As the number of sexual partners
increased, so did the likelihood of receiving the HPV vaccine. Receiving STD information from
one’s college/university also proved to be statistically significant in the regression analysis
(p=.005). There was an increase in the likelihood of receiving the HPV vaccine when receiving
STD information (OR=1.05, 95% CI=1.01-1.086).
The geographic region with the highest HPV vaccination rate was the Northeast (55%).
The Southern region had a HPV vaccination rate of 49%, followed by the Midwest and Western
region (45%). Differences in HPV vaccination rates between geographic regions was shown to
be statistically significant (p=.000) which is not surprising given the large sample size. Women
in the Midwest reported the highest rate of receiving a gynecological exam in the past 12 months
(60%). Northeast region women had the highest rate of receiving the Hepatitis B (93%) and
influenza vaccine (40%), and the highest percentage of health insurance coverage (98%). In the
binary logistic regression, women living in the Midwestern, Southern, and Western regions all
had a lower likelihood of receiving the HPV vaccine compared to those in the Northeast region.
The large sample size (N=68,193) provided by the ACHA-NCHA allowed for the
examination of several potential barriers to HPV vaccination. The chi-square analysis
demonstrated that there were statistically significant (p=.000) differences in HPV vaccination
rates between racial categories and geographic regions. The chi-square analysis also
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demonstrated that there were statistically significant differences (p=.000) in HPV vaccination
rates between women who did and did not have the Hepatitis B and influenza vaccine, and those
who did and did not have a source of health insurance. The results of the chi-square analysis
were not surprising due to the large sample size (N=68,193). The findings of the binary logistic
regression call for the rejection of the null hypotheses. The low pseudo-R2=.156 was most likely
due to the fact that there was a limited number of barriers included in the analysis. This study
could not determine perceived risk, perceived susceptibility, perceived benefits and cues to
action, which are arguably factors in deciding whether to engage in preventive health behaviors
(Brewer, et al., 2007, Nadarzynski, et al., 2012, McAlearney, et al., 2010).
Discussion
The CDC recommends HPV vaccination for women ages 18-26. The vaccine may offer
the benefit of decreased cervical cancer rates in women even after they have engaged in sexual
activity (Harper, et al., 2004, Goldie, et al., 2011). White/non-Hispanic women in the analysis
had the highest rate of HPV vaccination rates and the lowest rate of cervical cancer in the United
States when compared to other races (NIH, SEER Data, 2012). Gynecological exams often
include Pap testing. Minority women in this analysis demonstrated lower gynecological exam
rates compared to White/non-Hispanic women. In previous studies, it was shown that being a
member of a minority group was considered a barrier to HPV vaccination (Bendik, et al., 2011,
Kessels, et al., 2012, Licht, et al., 2010). Licht et al (2010) determined that Black and Asian
women were less likely to receive the HPV vaccine when compared to white women, which is
consistent with this analysis.
Increasing the rate of gynecological exams could be not only an avenue for Pap testing
but also for HPV vaccination recommendation: 55% of women in the analysis who had a
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gynecological exam in the past 12 months received the HPV vaccine, while 43% of women
received the HPV vaccine when they did not have a gynecological exam in the past 12 months.
The CDC (2008) reported that white women had a higher rate of gynecological exams, which is
consistent with this study.
Provider recommendation had shown to increase the likelihood of receiving the HPV
vaccine (Brewer, et al., 2007, Colgrove, 2006, Herzog, et al., 2008, Keating, et al., 2008,
Kessels, et al., 2012, Marchand, et al., 2012, Rosenthal, et al., 2011). When women are in
contact with health care providers, information regarding the benefits of preventive care can be
obtained. Physicians face barriers to recommendation of the HPV vaccine, such as low
reimbursement rates (Keating, et al., 2008). Promoting preventive care for college women can
also include education regarding the benefits of the HPV vaccine. Health care providers are an
important source of education regarding the HPV vaccine. Research needs to be expanded
regarding HPV vaccine recommendation among health care providers. The new recommendation
that women receive a Pap smear at 21, or three years after engaging in sexual intercourse, may
influence gynecological exam rates, which has to be determined by future research.
Women who received the Hepatitis B and influenza vaccine were more likely to receive
the HPV vaccine. Hepatitis B is often required for college matriculation, so it is not surprising
that 92% of respondents received the vaccine. What is interesting to note is that only 17% of
women who did not receive the Hepatitis B vaccine received the HPV vaccine. 64% of women
who received the influenza vaccine also received the HPV vaccine.
Women who had a source of health insurance were also more likely to receive HPV
vaccine. Respondents who reported that they were covered by parental insurance were almost
twice as likely to receive the HPV vaccine when compared to women who lacked insurance, as
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determined by the binary logistic regression (OR=1.845, 95% CI=1.689-2.016). Lower
socioeconomic status has been associated with lacking health insurance (Kahn, et al., 2008,
Rodriques, et al., 2005, Solomon, et al., 2007, Swan, et al., 2003). The CDC (2009) also
reported that insurance coverage is linked to increased gynecological exam rates. In this analysis
it was not possible to determine the students’ or parents income range, this is a limitation of this
analysis.
Age and number of sexual partners were statistically significant in the binary logistic
regression (p=.000). As women aged their likelihood of receiving the HPV vaccine decreased.
This is most likely due to lack of exposure to the HPV vaccination recommendation. The
recommendation came to fruition in 2006; however, women who are over the age of 19 in the
survey were past the target age of 11-12 at that time. It was also determined that an increase in
the number of sexual partners increased the likelihood of receiving the HPV vaccine. There may
be a misconception that it is best to get the vaccine after engaging in intercourse; in fact, the
opposite is true. Future research could be conducted to gain insight into when college women
believe that they should receive the HPV vaccine.
In the analysis receiving STD information increased the likelihood of getting the HPV
vaccine (OR=1.05, 95% CI=1.01-1.086). This was found to be statistically significant as well
(p=.005). The chi-square analysis determined a statistical significance in the HPV vaccination
rates of those who did and did not receive STD information. There was no way to evaluate the
STD information gained by the respondents, which is a limitation of the study. Past study
authors point to the need for tailored educational materials regarding the HPV virus and vaccine
(D’Urso, et al., 2007, Jones, et al., 2008, Kahn, et al., 2007, Parson, et al., 2000, Yacobi, et al.,
1999). Lacking knowledge concerning the HPV virus and vaccine is a barrier to vaccination
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(Blumenthal, et al., 2008, Brewer, et al., 2007, Rosenthal et al., 2011). Racially specific
educational materials could be viewed as practical in reducing the knowledge barrier. Bendik, et
al (2011) determined that HPV knowledge was an influencing factor in receiving the HPV
vaccine. Increased research regarding HPV education in college age women is warranted.
Strengths of the analysis
The greatest strength of this analysis is the large sample size afforded by the ACHANCHA (N=68,193). Most current studies which evaluated HPV vaccination in college women
had to rely on small sample sizes (Caron, et al., 2009, Caskey, et al., 2009, D’Urso, et al., 2007,
Kahn, et al., 2007, Licht, et al., 2010, Marchand, et al., 2012). Unprompted knowledge
concerning the rate at which college women receive STD information from their universities has
not been explored. Data regarding gynecological exams in the past 12 months was useful in
comparing HPV vaccination rates; both Pap smears and HPV vaccination aim to reduce cervical
cancer rates. Comparing HPV vaccination rates and Hepatitis B and influenza vaccination is
novel. Hepatitis B is a mandatory vaccine. The influenza vaccine is voluntary as is the HPV
vaccine.
Limitations of the analysis
This analysis relies on self-reporting. Limitations regarding self-reporting should be
acknowledged; response bias (the tendency to answer questions a specific way regardless of the
truth), lack of introspective ability of respondents, intentionally answering question inaccurately,
and the tendency of respondents to answer in a socially acceptable manner when asked sensitive
questions, such as “how many sexual partners have you had in the past 12 months.” Respondents
could also place themselves in multiple racial categories, eliminating the possibility of mutually
exclusive designations, which is highly desired in epidemiological studies. The analysis should
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not be generalized to all college age women, since the colleges/universities that participated in
the survey are self-selected.
There was no way to determine if the respondents received the full HPV vaccination
series; it can only be assumed that the respondents received one dose of the vaccine series.
There is no way to determine the content of the STD information received by the respondents.
The geographic regions in the study were limited to the four board categories defined by United
States Census Bureau. It would have been helpful to further divide regions of the United States
by state and rural and urban regions.
Conclusion
College age women between the ages to 18 to 26 are defined as a “catch-up” group when
targeting those that could benefit from the HPV vaccine. Some pediatricians are currently
advising parents of preadolescent and adolescent girls about the risks and benefits of receiving
the HPV vaccine. This targeting pattern is most likely due to the increased probability of sexual
encounters as girls reach their late teens. What is unclear is if women in the “catch-up” receive
HPV vaccine recommendations. While the HPV vaccine is best given before a girl’s first sexual
intercourse, there is a group of college age women that could benefit from the protection of the
vaccine.
There is limited research regarding college women and HPV vaccination. Most research
that has been done is on small populations in homogeneous college settings, or in single
institutional settings. This limited research, however, does point to a lack of general knowledge
and a deficiency in vaccination rates in college women. Examination of the variables that
empower or hinder these young women is warranted. Students of different racial background
may experience different barriers to HPV vaccination. As universities consider funding they
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need to justify the dollars spent on health education and services. Physician and other health
providers could also find that understanding the barriers to HPV vaccination for college women
may be appropriate when promoting the vaccine.
The Affordable Care Act (2010) not only aims to increase insurance coverage rates, but
specifically to decrease in health disparities in minorities. Understanding HPV vaccination
barriers in minorities could aid in the targeted health promotion. The possible creation of a
“medical home” for coordinated centralized care is a potential care model that is being explored
to increase adult vaccination in the United States. Currently women ages 18-26 may not have
been exposed to the HPV vaccination recommendation. There is the potential that women in the
catch-up group may suffer disproportionately from cervical cancer. This research could increase
the knowledge base concerning HPV vaccination rates and certain health behaviors of college
women.
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Chapter 2
Literature Review
Introduction
Human Papillomavirus
The Human Papillomavirus (HPV) is the most common sexually transmitted disease in
the United States. Like the flu virus, HPV actually describes a group of more than 150 related
viruses. Forty of the HPV viruses are spread by direct skin-to-skin contact, such as vaginal, anal
and/or oral intercourse. The virus enters the body through the epidermis, usually through a tear;
then epithelial cells are invaded and the virus develops proteins in cells which interfere with
normal cell growth, which ultimately can lead to the development of cancer. Condoms cannot
completely provide protection against HPV since skin-to-skin contact is still present, and other
forms of birth control, save abstinence, are not effective. HPV’s that are sexually transmitted are
placed into two categories, low risk and high risk. HPV types 6 and 11 are examples of the lowrisk category; these types are responsible for genital and/or anal warts. The HPV in the highrisk group are types 16 and 18, which are responsible for the majority of cervical cancers; type
16 is responsible for some oropharyngeal cancers. The National Cancer Institute reports that
42.5% of women have been exposed to the HPV strains that lead to genital infections and that
7% of adults have oral HPV infections. While women suffer from cervical cancer, men are more
susceptible to HPV oral infection (CDC, Cervical Cancer Fact Sheet, 2012, National Cancer
Institute, Cervical Cancer Fact Sheet, 2012, Dunne, et al., 2007). See Table 1 for common HPV
types, the corresponding disease, and signs /symptoms.
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Table 2.1:
Common HPV types: disease and signs/symptoms
HPV Virus Type
2, 7

Disease
common warts

Signs and Symptoms
Bumps on fingers and
hands
1,2,4,63
Plantar Warts
Raised cauliflower bumps
that occur on the soles of
the feet. These lesions
may bleed.
3,10,8
Flat warts
Flat lesions that may occur
on knees, elbows, wrists,
hands, and the face and
neck.
6,11,42,44
Anogenital warts
Flat or cauliflower lesions
that appear on the valve,
vagina, cervix, anus, penis,
and/or scrotum.
6,16,18,31,53,58
Anal lesions
Lesions that occur near or
around the anus.
16,18,26,31,33,35,39,45,51,52,53,56, Genital Cancers
Pre-cancerous and
58,59,66,68,73,82
cancerous formation in the
genital area; visible lesions
are often observed. This
includes cervical cancer.
13,32
Focal epithelial hyperplasia Pre-cancerous lesions that
are found on the lips,
cheeks, sides of the tongue.
The lesions are often flat
and asymptomatic.
6,7,11,16,32
Oral papillomas
Benign lesions that may
appear on the lips, inside of
cheeks, and/or tongue.
16
Oropharyngeal Cancer
Cancerous lesions that may
appear on the base of the
tongue, tonsils, soft palate,
and/or pharynx
6,11
Laryngeal papillomatosis
Benign lesions that appear
on the larynx that can
cause loss of voice and
difficulty breathing.
*Centers for Disease Control and Prevention, HPV type, 2012
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HPV infection is difficult to detect since the majority of infections are asymptomatic.
Infections are often transient, resolving in one to two years. Determination of cancer formation
due to HPV is not possible since it is difficult to determine when the virus will or will not
become transient. Predicting HPV infection, the progression or remission, proves to be difficult
(Goldie, et al., 2003).

Several factors increase the likelihood that the virus will cause genital

warts or cancer. These factors include a weakened immune system, multiparity (having multiple
children), long-term use of oral contraceptives, poor oral hygiene, smoking, and chronic
inflammation. Treatment for HPV-induced cancer includes surgery (removal of pre-cancerous or
cancerous lesions), chemotherapy for cancerous lesions that are at risk for dissemination, and
radiation therapy for local control of cancerous lesions. The common treatment of genital warts
includes surgery and/or topical drugs (CDC, Sexually Transmitted Diseases Treatment
Guidelines, 2010).
Cervical cancer rates in the United States
In the United States, the CDC reported that in the time period 2004-2008, 11,967 women
on average were diagnosed annually with HPV-associated cervical cancer and 4,008 women
died. The CDC also reported that during the same era, 11,726 cases of HPV-associated
oropharyngeal cancer were diagnosed annually, of which 9,356 were diagnosed in males.
Cervical cancer rates (HPV and non-HPV associated) are higher among blacks (9.9%) and
Hispanics (11.3) compared to whites (7.4%) and non-Hispanics (7.4%). This disparity is likely
related to socioeconomic status and decreased access to screening and follow-up (Cervical
Cancer Rates, 2012, Morbidity and Mortality Weekly Report, April 2012, Zambrana, et al.,
1999). Cervical cancer rates are determined by the National Center for Health Statistics; the
Comprehensive National Health Interview Survey is the non-institutional national survey that
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was employed, and statistics were compiled by the Centers for Disease Control (Swan, et al.,
2003, CDC, Cervical Cancer Rates, 2012, NIH, SEER Data, 2011).
According to the American Cancer Society (ACS) and the Surveillance Epidemiology
and End Results (SEER), cervical cancer typically occurs in women between the ages of 35 to
55, with the median age at diagnosis being 48. Black and Hispanic women have a higher
incidence rate compared to white women: 9.8 cases per 100,000 black women and 11.8 per
100,000 Hispanic women, compared to 8.0 per 100,000 for white women. Black and Hispanic
women also have a higher mortality rate: 4.3 per 100,000 black women and 3.0 per 100,000
Hispanic women, compared to 2.2 per 100,000 white women (NIH, SEER Data, 2012). The high
risk (oncogenic) strains of HPV (Types 16, 18, 31, 33, and 45) are responsible for about twothirds of all cervical cancers in all races, with strains 16 and 18 being the most common.
Currently, there is no cure or treatment for HPV infection. There is only treatment for healthrelated problems caused by HPV.
The 2003 Youth Risk Behavior Surveillance summary reported that 62.3% of females in
the United States have had sexual intercourse by the time they graduate from high school (Cates,
2007), which indicated that possible HPV infection can occur at a early age. The National
Health and Nutrition Examination Survey, which provided a representative sample of the United
States, used self-collected vaginal swabs to conclude that HPV was prevalent in 26.8% of US
females ages 14 to 59. The prevalence of HPV in women 20-24 years of age was 27.4% (Dunne,
et al., 2007). The authors of the study “Prevalence of HPV Infection among Females in the
United States” concluded that while HPV infection is widespread, the incidence of infection by
HPV types (16/18) that are responsible for the development of cervical cancer is relatively low,
at 1.5% (Dunne, et al., 2007).
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Global cervical cancer rates
The World Health Organization (WHO) reports that internationally, cervical cancer rates
remain high. Globally there are approximately 500,000 confirmed cases of cervical cancer and
275,000 deaths. Worldwide, cervical cancer is a leading cause of cancer-related mortality among
women. In North America, cervical cancer is the 13th leading cause of cancer deaths; however,
in developing regions such as Africa and Southeast Asia, cervical cancer is the second leading
cause of cancer death among women (WHO, Global Cancer Statistics, 2010). East Africa has
the highest rate of cervical cancer worldwide. Lack of patient screening in East Africa, due to
lack of health delivery systems, health care workers, and limited health care budgets, is the major
factor in the large number of cervical cancer deaths (Campos, et al., 2012, WHO, Global Cancer
Statistics, 2010). Established screening practices and increased access to health care facilities
have decreased the cervical cancer burden in the United States and other Western nations. The
demographic group that has not experienced a decrease in cervical cancer rates is Hispanic
women (Vizcaino, et al., 2000). The benefits of cervical cancer screening and HPV vaccination
have not been realized in developing countries.
Screening practices in the United States for cervical cancer
In the United States screening for pre-cancerous and/or cancerous lesions of the cervix is
done with the use of cervical cytology testing. This test is called the Papanicolaou test, which is
commonly known as the Pap smear. A healthcare provider, commonly a gynecologist, family
practitioner or advanced practice clinician, will introduce a speculum into the vagina to collect
cells from the outer opening of the cervix. The collected cells are placed under a microscope to
detect any pre-cancerous (cervical intraepithelial neoplasia) or cancerous lesions. The sensitivity
rate for detecting high-grade cervical lesions is 60-80%, which has proved beneficial in detecting
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cervical cancers (USPSTF, Screening for Cervical Cancer, 2012). The United States has
decreased its cervical cancer rates by 80% since 1950, largely due to Pap smear testing (NIH,
Cervical Cancer Facts, 2012). Until recently it was recommended that females obtain a yearly
Pap smear after the initiation of sexual intercourse, regardless of age, or after the age of 18. As
of March 2012 the screening guidelines for cervical cancer have changed (ASC, Cancer
Screening Guidelines, 2012).
The United States Preventive Services Task Force (USPSTF), which is sponsored by the
Agency for Healthcare Research and Quality (an independent task force comprised of experts
who analyze scientific evidence to ensure that preventive services are effective), along with the
American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology,
and the American Society for Clinical Pathology, released new screening guidelines. It is now
recommended that women have their first Pap test at the age of 21 or three years after first
intercourse. These new recommendations are due to the fact that HPV is often transient, if a
woman in her 20’s is infected with HPV 16 or 18; there is a high likelihood that the infection
will clear her body within two years. Cancerous lesions are extremely rare in women under the
age of 40. The updated guidelines suggest that women 21-29 years receive the Pap test every 3
years; it is recommended that women 30-65 receive the Pap test every 3 years, or every 5 years if
testing for HPV is negative (ASC, New Screening Guidelines for Cervical Cancer, 2012, Dunne,
et al., 2007, Smith, et al., 2007, USPSTF, Screening for Cervical Cancer, 2012).

The impact of

these new guidelines could possibly result in decreased healthcare costs (Solomon, et al., 2007).
The CDC reports that Pap smear rates between the years 2000-2008 have fluctuated by
race for women 18 and older. In 2000, 81.3% of white women received the test, and in 2008 that
percentage fell to 74.9%. Black and Hispanic women showed the same trend. In 2000, 85.1% of
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black women received a Pap test, while in 2008 only 80.1% did; 77% of Hispanic women had a
Pap smear in the year 2000 and 75.4% in 2008 received the test. Asian women demonstrated the
lowest percentage (65.6%) who received a Pap smear in 2008. The CDC also reported that the
percentage of women who received the Pap test varied by educational level. In 2008, 82.6%
women with some college received a Pap smear, while 69.5% of women with only a high school
diploma, and 60.6% of women without a high school diploma, received a Pap smear. Age was
also a factor in Pap testing; 81.8 % of women age 18-44 compared to 78.8% of women age 45-64
years old opted to receive a Pap smear (CDC, Surveillance of health status in minority
communities, 2009).
Survey studies have concluded that being a member of an ethnic minority and a lower
socioeconomic status can lead to decreased cervical cancer screening rates (McAlearney, et al.,
2010, Rodriques, et al., 2005, Solomon, et al., 2007, Swan, et al., 2003, Vanslyke, et al., 2008).
Michael A. Rodriques, et al., in the 2005 study “Breast and Cervical Cancer Screening; Impact
of Health Insurance Status, Ethnicity, and Nativity of Latinas,” demonstrated that lack of health
insurance is a major determining factor in breast and cervical cancer screening rates. 1998 data
from the California Women’s Health Survey determined that 9% of foreign-born Latinas and 7%
of U.S.-born Latinas did not receive a Pap smear; the largest predictor found in a multiple
regression analysis was lack of health insurance. Knowledge of HPV is increasing; however,
Hispanic women had a lower knowledge rate (67.1% vs. 78.9%) than non-Hispanic women
(Kobetz, et al., 2010). Additional barriers to screening include low socioeconomic status and
education levels. For example, Appalachian Ohio had higher cervical cancer rates, 37% above
the national average for white women (McAlearney, et al., 2010). Living in a non-urban area is
also a contributing factor for lower Pap smear rates (Swann et al., 2003, McAlearney, et al.,
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2010, Pruitt, 2010). Overall, cervical cancer screening with the use of Pap smears has decreased
cervical cancer rates in the United States by 70% since the 1930’s (ASC, New Screening
Guidelines for Cervical Cancer, 2012, USPSTF, Screening for Cervical Cancer, 2012). The
National Cancer Institute reported in 2005 that 47% of women over 18 were aware that HPV
caused cervical cancer, and in 2007 the awareness grew to 78%. This increase in awareness may
be contributed to increased media coverage of the vaccine and approval by the FDA.
Testing for HPV in Pap specimens is not routine. Cells gathered from the cervix can be
tested for the presence of high risk HPV (16/18) deoxyribonucleic acid (DNA). The CDC only
recommends this test for women over the age of 30 or for women over the age of 21 who had an
abnormal Pap smear. The DNA test for HPV could become an adjuvant procedure for women
who have had abnormal Pap smears in the past. There is no reliable blood test for HPV. The
2006 introduction of the HPV vaccine to prevention regimens may have the potential to further
decrease cancer deaths (CDC, Cervical Cancer fact sheet, 2012).
Human Papillomavirus vaccination
The Federal Drug Administration currently has approved two vaccines, Gardasil®
(Merck & Co.) and Cervarix ® (GlaxoSmithKline). Gardasil protects against HPV types 6, 11,
16, and 18, strains that are linked to both cancer formation and genital warts. Cervarix ®
protects against HPV types 16, 18, 45 and 31 and offers protection against anal cancers. The
vaccine is recommended for girls ages 9-26 and males ages 11-21, with routine vaccination for
girls and boys aged 11-12. The FDA-approved regimen is three separate vaccinations over a
three-month period (CDC, Cervical Cancer fact sheet, 2012, NIH, Cervical Cancer fact sheet,
2012). Reported side effects of the vaccines include pain, pruritus (itching), erythema (redness
of the skin) and swelling at the injection site. There is insufficient evidence at this time to
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determine if a booster will be needed at some period following the initial vaccination (CDC,
Cervical Cancer Fact Sheet, 2012, Dempsey, et al., 2008, Goldie, et al., 2011, NIH, Cervical
Cancer Fact Sheet, 2012). Multiple strains of HPV can co-exist and have a synergistic
relationship. Vaccination may curb this synergist relationship. “Vaccination against multiple
HPV types” used mathematical modeling to demonstrate that mass vaccination against the
specific strains of the virus could lead to decreased coexisting HPV infections and future HPV
infections (Elbasha, et al., 2005). Women and men could benefit from the HPV vaccine, as it
offers not just protection against cervical cancer but also oropharyngeal, penile, and anal cancers
(Kim, et al., 2008, NIH, Human Papillomavirus, 2012).
In 2011 28.1% of females between the ages of 13-17 received all three doses of the
vaccine series; the uptake rate for the hepatitis B three-dose series is 92.3%. The target HPV
vaccination rate stated in Health People 2020 is 80%. Adolescent females that live below the
poverty line have a lower rate of vaccination series completion than those that are at or above the
poverty line (CDC, Morbidity and Mortality Weekly Report, 2011). Increase in vaccination
rates is often based on several factors. The systemic review “Factors associated with HPV
vaccine uptake in teenage girls” demonstrated that having health insurance, receiving regular onschedule vaccines, increased health provider visits, and positive parental attitudes regarding
vaccination are all factors in uptake (Kessels, et al., 2012). It was also demonstrated that black
females were less likely to receive the vaccination series. The authors discussed the need to
create vaccination programs that focused on specific racial/cultural groups to lessen disparities
(Kessels, et al., 2012).
The vaccine is also considered effective in women between the ages of 15-26. Harper, et
al. (2004), conducted a randomized controlled trial in young women. They found that Gardasil®

32

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

was 95% effective in preventing HPV (16/18) infection in women that tested negative for HPV,
had less than six sexual partners, and had a history of no abnormal Pap results. The authors felt
that women could benefit from the HPV vaccine and that widespread use of the vaccine could
decrease HPV rates worldwide (Harper, et al., 2004). Women who lack access to screening Pap
smears could realize the greatest benefit from HPV vaccination. Lack of access to Pap screening
is high among Hispanic women and those of lower socio-economic status, and the benefit of the
HPV vaccination could drastically reduce cervical cancer rates (Brewer, et al., 2007). The
transient and synergist nature of the virus makes it difficult to provide clear statistics on the
protection rate of the vaccine in sexually active women (Elbasha, et al., 2005, Harper, et al.,
2004).
In the 2009 national survey study “Knowledge and Early Adoption of the HPV Vaccine
Among Girls and Young Women: Results of a National Survey” it was reported that 9% of
women over the age of 18 received at least one dose of the HPV vaccine even though 86% of
respondents had heard of the vaccine and 91% had heard of the virus. Forty one percent of the
respondents had some college experience and 19% obtained a bachelor’s degree. Sixty four
percent of the females between the ages of 18-26 were white, with the remainder being Hispanic
or black, and the researchers found that race had no influence on vaccination status. The
multivariate predictors for vaccination included having a regular healthcare provider and visiting
a provider within 6 months (Caskey, et al., 2009). The results were similar in a systemic review
compiled in 2007: vaccine acceptability was associated with physician recommendation, and
race was not a variable in acceptability (Brewer, et al., 2007).
Race was a predictor for HPV knowledge, vaccine acceptability, and related beliefs
among rural Southern women (Cates, et al., 2009). When controlling for income, age, and
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location the interview study determined that blacks were less likely than whites to believe that
HPV was a threat and they reported lower intentions to vaccinate their daughters. While this
study was limited to a single state, they concluded that blacks were less knowledgeable
concerning the benefits of the HPV vaccine (Cates, et al., 2009). Fazekas, et al. (2008), found
that Southern black women had a higher intention to vaccinate their daughters when they were
more knowledgeable about the HPV virus. The measures of this study included awareness,
knowledge, attitudes regarding HPV and vaccine acceptability (Fazekas, et al., 2008).
HPV vaccine acceptance by parents and young women has been shown to be influenced
by health provider recommendation. Providers are in turn are more likely to recommend the
vaccine if their medical profession organization(s) recommend the vaccine, other barriers still
exist including patient cost and physician reimbursement (Keating, et al., 2008, Zimet, 2006). A
phone survey study by Keating, et al., focused on a geographic region which has a high cervical
cancer rate. The researchers asked medical practices what their concerns were with offering the
HPV vaccine; 68% responded that low reimbursement rates were the major concern. The overall
cost of the vaccine series was a concern for 66% of the respondents; the average cost of the
vaccine series is $320.00. The stocking of a vaccine upfront while waiting for private insurance
reimbursement was the strongest physician barrier (Keating, et al., 2008).
Education regarding vaccines aimed at juveniles is commonly geared toward physicians
and parents. The fact that the HPV infection is sexually transmitted complicates the willingness
of some groups of parents to vaccinate their daughters and of physicians to engage in
uncomfortable conversations with patients and/or parents (Kating, et al., 2008, Kessels, et al.,
2012, Zimet, 2006). Politicians have found that mandating the HPV in adolescent females is not
without controversy. Parental confidence in the vaccine varies; vaccine safety is a concern, as
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well as the vaccine’s effect on the sexual behavior of vaccinated adolescent girls. Parental
acceptance is based on many factors such as knowledge of the HPV virus, religious views, and
physician recommendation (Colgrove, 2006, Herzog, et al., 2008, National Conference of State
Legislatures, HPV vaccination, 2012). There is no research that links HPV vaccination and
increased promiscuity in teenagers or young women.
In a 2005 study of over 600 pediatricians, Kahn and associates showed that HPV
knowledge and attitudes about vaccination were predictors of intent to vaccinate. Although this
study was done prior to the approval of Gardasil®, important information about pediatricians’
perceptions and attitudes was developed. Patients and parents rely on healthcare providers to
advise them on health choices. When individuals are not in direct contact with health care
providers, important information may be not be given to those that need it most. In the United
Kingdom, research regarding public knowledge and attitudes about HPV has increased. Even
though the vaccine was widely accepted in the UK, knowledge about the virus is minimal. A
primary recommendation from the study “Public Knowledge and attitudes toward Human
Papillomavirus (HPV) Vaccination” was that the Public Health Service in the UK should focus
on education to address questions regarding side effects, efficacy, and cost (Walsh, et al., 2008).
As the UK explores implementation of the HPV vaccine, there is the realization that
implementation is complex and education of healthcare providers and the public is essential.
The public health system in the UK has the resources to follow women for several decades to
evaluate the efficacy of the vaccine. Cost as a barrier to vaccination in the UK exists, as the
National Health Service does not cover the vaccination series for women over the age of 18
(Adams, et al., 2009, Raffle, 2007).
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The United Kingdom and Australia have implemented comprehensive HPV vaccination
schemes. Government-funded vaccination programs are not only for adolescent girls; the
vaccine also is offered to the 18-26-year-old catch up group. In Australia 84% of 12-13-year-old
girls and 52% of 20-26-year-old women have received the first dose of the HPV vaccine. In the
United Kingdom the vaccine is part of the standard vaccination program for adolescent girls and
62% of 18-26-year-olds in the catch-up group are vaccinated (Gertig, et al., 2011). National
health care programs have allowed the United Kingdom and Australia to maintain a National
Vaccination Register, and develop large-scale vaccination strategies (Gertig, et al., 2011).
Currently there is no adult vaccination register in the United States.
Public awareness of HPV and its links to cancer have been shown to increase uptake.
Despite the HPV vaccine’s benefits, however, it is important to communicate that the vaccine
does not provide 100% protection against cervical cancer (Brewer, 2007). If information
regarding the HPV vaccine is not properly and accurately communicated, officials fear that the
vaccine may be considered a safeguard to cervical cancer and the United States could see a
decline in compliance with cervical cancer screening guidelines. Vaccination appears to provide
nearly 100% protections against only five oncogenic types of HPV, as long as the individual is
not already infected. According to Slomovitz and Bodurka (2007), organizations including the
American Academy of Family Physicians and the American Academy of Pediatrics believed that
mandating the vaccine was premature. Regardless of such opposition, and the trend in medicine
to introduce highly specific treatments/vaccinations based on genetically encoded information,
policy makers in the United States will need to be given relevant, accurate, and ethnicallysensitive information.
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Strong endorsement from the medical community is needed to move forward with mass
vaccination programs. In 2004, Raley, et al., demonstrated that endorsement by a professional
organization, and reliable information that the vaccine would be successful, were major factors
in physician recommendation practices. In a systemic review of 28 studies from 1995-2007
regarding HPV-related beliefs and vaccine acceptability, Brewer and Fazekas (2007) showed
that in establishing vaccine programs importance should be placed on vaccine effectiveness, the
likelihood of infection, physician recommendation, and barriers to implementation. The authors
demonstrated that 42% of individuals were aware of HPV, 21% knew that the virus was
common, 59% knew the purpose of Pap smears, and 68% knew that HPV is an STD. Limited
knowledge of the virus may make it difficult to determine acceptability of the vaccine (Brewer,
et al., 2007).
Health Belief Model
The Health Belief Model (HBM) was first described in the 1950s by Hochbaum,
Rosenstock and Kegels. This social cognition model is often used to explain and predict health
behaviors. The constructs of the model are: perceived susceptibility, perceived severity,
perceived barriers, perceived benefits and cues to action. Human behavior and variability is
complex and often subtle, and so constructs were developed to offer a tested approach to modify
health behaviors (Becker, 1974). The challenge for government agencies that approve and
license vaccines and the professionals who inoculate and educate the public is to convey accurate
information and carefully construct a plan for appropriate dissemination of that information
(Nadarzynski, et al., 2012). Providing information on only the risk of cervical cancer did not
reduce cervical cancer risk perception. However, providing information regarding HPV as well
as behavioral risk factors was more meaningful. In studies both in the United States and the
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UK, it was shown that providing information on cervical cancer risk factors lowered women’s
perceptions that they were at risk. This shows that certain forms of education can lower
perceived risk, while including information regarding HPV increased perceived risk
(Nadarzynski, et al., 2012, McAlearney, et al., 2010). Since the HPV vaccine has already been
licensed, and in some states mandating the vaccine is debated, health professionals should
understand the barriers that women 18-26 would face. The recommendation by the CDC that
women 16-26 receive the vaccine is not the only factor that influences the decision-making
process.
Addressing barriers to HPV vaccination can aid individuals in addressing their risk and
realize the possible benefits. Offering free vaccination programs is often not enough. In 2011
Giambi, et al. evaluated a health program in Italy, and the major problem identified was
maintaining contact with young women. Only 53% of women vaccinated in the program
received all three doses of the vaccine. The authors concluded that they needed increased
contact with young women, and a more efficient way to maintain contact to ensure the
completion of the vaccine series (Giambi, et al., 2011). Public awareness of HPV may be a
vehicle for increased HPV vaccination in the catch-up group: in a 2007 study of the awareness of
the link between HPV and cervical cancer in the UK, only 2.5% of the survey respondents could
indicate they knew of the link (Marlow, et al., 2007). Reaching women in the contact group and
maintaining contact is necessary.
Kahn, et al. (2007), concluded that clinicians may be able to promote healthy
reproductive behaviors while educating adolescent and young women about HPV and Pap test
results. These authors explored educating young women based on the HBM, collecting
information about perceived risks and threats as well as personal beliefs about personal
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accountability. Interestingly, because this infection is transmitted sexually, it was anticipated
that the shame and stigma caused by the disease would in turn lead to inappropriate self-care and
follow-up. Kahn, et al. (2007), recommended that clinicians communicate accurate information
based on an individual’s personal experiences. It was recommended that this information be
delivered in a non-judgmental manner to reduce the stigma of contracting an STD (Kahn, et al.,
2007).
Brewer and Fazekas (2007) reviewed fifty-three relevant articles focusing on the
acceptability of the HPV vaccine among adolescents, young adults and parents of adolescents in
the United States. As with any new vaccine or medical intervention, there must be awareness and
knowledge of the issue. Within the HBM construct, perceived risks and effectiveness of the
vaccine and the cues to action are important predictors of success. Perceived risk of HPV must
include the close association of HPV with cervical cancer; personal risk plus severity of the virus
may increase the perceived threat. If the risk of being infected with HPV is greater than the risk
factors associated with actual vaccination, then the likelihood of accepting the vaccine is greater.
Barriers to vaccination include cost, side effects, and safety. The vaccine’s cost is approximately
$120 per shot, but it is available through Medicaid and many private insurance programs. The
long term safety and efficacy of the vaccination has not been fully researched and consequently
remains a concern among Americans (Garland, et al., 2007). Since HPV is a sexually transmitted
infection, the issue of vaccination becomes more than just a medical issue. There is a concern
among some parents that vaccination could promote adolescent sexual activity (Brewer, 2007).
Since vaccination is recommended for girls as young as nine years old, the issue of the HPV
vaccine is a highly charged topic with widely varied opinions. According to Charo (2007), many
states are considering mandatory vaccination for school age children but are providing an option
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for parents to decline based on religious or philosophical objections. Charo (2007) states that “in
the case of HPV vaccine, parents’ belief that their children will remain abstinent (and therefore
uninfected) until marriage renders it even more difficult to make the case for mandating a
medical form of prevention.” Many consider HPV vaccine mandates as unwanted and an
unnecessary intrusion on personal and parental rights; the statistics would argue, however, that
abstinence-only approaches cannot be relied upon (Cates, 2009).
Kahn, et al. (2007), explored perceptions regarding abnormal Pap and HPV results. The
authors followed a group of 100 sexually active females, aged 14 to 21 years, from an urban teen
health center. This mixed-method study revealed a significant increase in HPV knowledge
following a 20-minute standardized educational protocol. Through interviews, the authors
explored the group’s perceptions of severity, susceptibility and beliefs about personal
accountability. Interestingly, guilt was commonly mentioned when asked how they would feel if
they were to test positive for HPV or have an abnormal Pap smear. There was discussion
regarding anticipated shame and stigma associated with HPV. They described social isolation
and rejection with words such as “dirty,” “nasty” or “promiscuous.” Educational programs
geared toward young girls and women should carefully consider the anxiety and distress that
may result from a positive Pap test. These psychosocial stressors may manifest themselves in
shame or guilt, which may lead to inappropriate treatment and follow-up (Kahn et al., 2007).
Cues to action with respect to the HPV vaccine seem to be varied across socioeconomic
status (SES) levels. Parents of lower SES are more willing to have their teen vaccinated. In a
2007, authors Slomovitz and Bodurka found in a small pilot study of 200 women that 77%
would be willing to be vaccinated themselves, while only 67% would be willing to have their
daughter vaccinated. Reasons for their hesitation included vaccine effectiveness and side effects.
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Brewer and Fazekas (2007) noted that parents were more likely to accept the vaccination if it
was physician recommended and a school requirement. Other potentially important factors
regarding parents’ cues to action include the age of their child and awareness of sexual activity.
Political and religious conservatives were also less likely to accept the HPV vaccine for their
daughters (Brewer and Fazekas, 2007). Race is also a factor in awareness, knowledge, and
beliefs related to HPV vaccination. In a rural Southern population, blacks reported a lower
intention to vaccinate their daughters compared to white women in the same geographic location
and SES; blacks were also more likely to believe that the vaccine was best delivered after the age
of 17 (Cates, et al., 2009). Demographics and SES should be factors when designing education
strategies for HPV vaccine delivery (Fazekas, et al., 2008).
According to Kahn, et al. (2005), parents rely on pediatricians to recommend
vaccinations and other health interventions. The survey utilized in their study was based on the
Theory of Planned Behavior, a model that has been used to predict physician behaviors. In
particular, these behaviors include delivery and/or recommendation of immunization practices.
The physicians were surveyed regarding knowledge of HPV and attitudes toward vaccination. It
was found that knowledge regarding HPV, including vaccine safety and other characteristics,
provides the pediatrician with important information that may impact his/her intention to
administer the HPV vaccine. Another study (Keane, et al., 2005) dovetailed nicely with the
aforementioned study, as it describes what has to occur for parents to understand and accept this
vaccination. In contrast to the parents of the group of adolescents surveyed (Kahn, et al., 2005),
the paper by Keane and associates placed more importance on vaccine safety, efficacy and cost.
It clearly will take a “coming together” of the medical and public health communities as well as
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parents to understand and take a proactive role in the health and safety of those children that are
at risk for HPV and consequently, cervical cancer.
Social media also plays a role in the dissemination of HPV vaccine information. A 2010
Gardasil® commercial features young girls in a wide variety of activities proclaiming “One
Less,” that is, one less cervical cancer case because they received the HPV vaccine. Presently,
there are public service announcements advocating HPV vaccines but the frequency of airing and
viewership is not known. Aside from these paid advertisements, information regarding the
vaccination remains elusive unless an individual is uniquely interested. Information and
misinformation abounds on the Internet and print materials, consumers must be careful of their
sources when searching for information regarding the HPV virus (Brandt, et al., 2005). In a
YouTube content analysis of information presented on HPV and cervical cancer, 75% was
positive in nature but the majority was not professionally directed and additional information
could have been presented (Ache, et al., 2008). In the mass media, important information
regarding the virus is still missing, such as silent symptoms and how condoms do not guarantee
protection against HPV infection (Kelly, et al., 2009). The media is a source of both positive
and negative information and as a result, healthcare providers are still a vital source of
information regarding HPV. Anti-vaccination web sites commonly communicate that
vaccinations of various types cause illness, erode immunity, and are developed mainly for profit
(Wolfe, et al., 2002). Social media can play either an informative role or a vehicle for
misinformation.
Keane, et al. (2005), cited doctors, family/friends and nurses as the top three sources of
credible information regarding vaccines. Parents were divided into groups based on their
acceptance of vaccines (Vaccine believer, Cautious, Relaxed, and Unconvinced). Factors and
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beliefs evaluated in the study included vaccine safety, vaccine recommendations, school
requirements, disease protection, necessity of vaccines, relationship to child, role of government
and trust in products. Keane concluded that customized communication has the best chance of
success. Messages, educational materials and time spent with parents should be tailored to
parents’ individual needs. Government and community agencies may accept these
recommendations and develop tailored messages for each of the parent groups described in this
study (Keane et al., 2005).
College women and HPV vaccination
The Health Belief Model (HBM) provides a reasonable model by which health educators
and health care professionals can work to provide appropriate interventions and strategies for
increasing the uptake of the HPV vaccine. The HBM and HPV screening with the Pap test in
college women was explored by Burak, et al. (1997). The construct of the HBM explained only
15% of the variance in screening. However, their study showed that 80% of the participants
believed that they were not susceptible to STD’s when, in fact, they were. This was a pilot study
and the sample was small and homogeneous. Barriers examined included cost, pain, and
embarrassment. Results showed that 99% of the participants believed that STD’s and cancer
were serious, 52% had abnormal Pap smear tests, and 90% believed that gynecological exams
are very important. The majority took cues to action from their mothers and only 32% had any
knowledge of student health services; 16% were concerned that they were in danger of
developing cervical cancer. There was a disconnection between the need for Pap smears and
HPV susceptibility. Examination of each construct may allow health promoters to measure why
individuals or groups of individuals elect to seek treatment or prevention (Burak, et al., 1997).

43

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Larger sample sizes and expanded surveys may yield more information on the belief systems of
different demographic groups.
The HPV vaccine is relatively new and researchers have been exploring knowledge,
perceptions of the benefits, costs, and personal meaning in college age women (D’Urso, et al.,
2007, Kahn, et al., 2007, Parsons, et al., 2000, Yacobi, et al., 1999).

Kahn, et al., stated in their

qualitative interview study that cognitive understanding of HPV influences behavior, as does
understanding of Pap test results. Susceptibility to future HPV infection may be negatively
influenced by a negative Pap smear and so a “my test is negative I do not need to worry”
mentality may emerge. A negative Pap smear does not clear them of the future dangers due to
HPV infection, but the sentiment may develop (Kahn, et al., 2007).
In the 2007 study “HPV Knowledge and Behaviors of Black College Students at a
Historically Black University,” 64% of the 351-student sample had never heard of HPV and
those that were aware of the virus gained their knowledge from a healthcare provider. Even
those who had knowledge of HPV had many misconceptions: 36% believed that HPV caused
Herpes and 65% believed HPV caused burning during urination (D’Urso, et al., 2007). When
seven common STD’s -- HPV, HIV, Chlamydia, Gonorrhea, Herpes, Hepatitis B, and Syphilis -were listed, the subjects knew the least about HPV (Yacobi, 1999). Lack of knowledge and
misinformation is a common theme in current research. While many young women gather
information from their mothers on gynecological issues, HPV is not entering the awareness of
many college age women.
Conversely, a 2009 study done at a large state university in New Hampshire found that
85% of the 361-female sample knew what HPV was and 85% knew about Gardasil ® (Caron, et
al., 2009). This study stands out as overwhelmingly positive. The data collection took place in
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University Health Services; employees distributed surveys while female students waited for their
appointments. Surveys also were given out in a health class, aerobics class, and choral rehearsal.
Women taking part in this study may have been educated on HPV in their educational
environments and women using health services may have been more aware than other students
because they were more health conscious. However, it is worth noting that even though sexually
active women in this study were aware of HPV, only 56.5% believed they were at risk of being
infected by the virus (Caron, et al., 2009).
College-age men and their knowledge and perceptions of HPV have been the subject of
very limited research. A small and homogeneous sample size was used at a university to
demonstrate that men had little knowledge of HPV: 54.9% had not even heard of the virus. The
166 men in the sample, mostly white, did not perceive themselves at risk of HPV, even though
the participants, who were knowledgeable, believed the infection was severe for women. The
encouraging statistic in this study was that 95% of the men stated they would use a condom if
they were diagnosed with HPV (McPartland, et al., 2005). While both female and male 20-yearolds may have knowledge of genital warts, the knowledge that HPV caused genital warts is
lacking (Baer, et al., 2000). This limited research points to a greater need for education not only
in women but also in male college-age groups.
Brief educational intervention has been shown to increase knowledge of HPV from 45%
to 79% in a small sample of college women (Lambert, 2001). Again, there is no study that
points to a common knowledge base in women, so one type of educational intervention may not
be appropriate for all populations of women. Lambert was able to demonstrate that HIV
knowledge outranks HPV knowledge even though HPV is the most common STD and can lead
to lethal cancers. There is no link between high school graduation and high school location and
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increased knowledge of HPV, which could point to a wide spread lack of emphasis on HPV
education. HIV-specific education has been highly effective in informing individuals of their
risks and changing their behaviors. Approaching HPV education in a similar manner may, in
the future, yield similar results (Lambert, 2001, Yacobi, 1999).
HPV knowledge, perceptions, and motivation to receive the vaccination in college
women were explored by Bendik, et al., 2011. Using an email survey in a large Southeastern
university that employed knowledge and behavior items modeled after the National College
Health Survey, the researchers determined that only 30.4% knew that HPV was the most
common sexually transmitted disease, even though 40.4% of sexually active females, 39.1% of
white students, 19.6% of black students, and 37.9% of Hispanic students received the HPV
vaccine. Using a biserial analysis, significant factors in vaccination uptake were perceived: the
importance of HPV, severity of cervical cancer, perceived likelihood of acquiring cervical
cancer, knowledge of HPV, and increased number of sexual partners. Bendik, et al used their
data to emphasize that educational intervention could be an avenue to increased HPV
vaccination, as knowledge was an influencing factor in receiving the HPV vaccine. The authors
stated that a limitation of the survey study was that 90% of respondents were white. A more
heterogeneous population could be a focus of future research (Bendik, et al., 2011).
Kahn, et al. (2008) reported the rates of HPV infection in a population of low income
women recruited from a teen health center and Department of Health clinic. Females (n=409),
ages 13-26, completed a questionnaire regarding intention to receive the HPV vaccine series and
their belief that they could receive the vaccine. Twenty-five percent of the sample was uninsured
and 55% utilized Medicaid. Additionally, 100% of participants underwent HPV DNA testing.
HPV vaccination history was gathered along with demographic information, gynecologic history,
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insurance status, sexual behavior (number of partners and type of birth control used), and beliefs
about HPV and vaccination. Constructs used in this study were based on the Theory of Planned
Behavior, Social Cognitive Theory, and the Health Belief Model. Using summary statistics for
HPV vaccination, demographics, attitudes, and HPV infection, it was reported that 5% had
received one dose of the vaccine, 68% were infected with HPV (17% with type 16 and 12% with
type 18). Sixty-six percent intended to receive the vaccine, 54% believed they could receive the
entire three shot series, and 42% believed that they could afford the series. Factors found to be
significant in the logistic regression included perceived severity of HPV, past STD history, and
insurance coverage, all of which had a positive correlation. A limitation of this study was that
the sample was limited to girls/women with self-reported previous sexual contact.
Caskey et al. (2009) utilized an existing national research panel to obtain 1,011 women
ages 13-26 for analysis. This study used a survey to gather health characteristics that included
healthcare utilization, tobacco use, sexual activity (number of sexual partners, age of first
intercourse, and history of past STD’s), outcome of previous Pap smear tests, knowledge of HPV
and its’ protective vaccination, and belief in condom use after vaccination. It was determined
that 75% of the 599 women between the ages of 18 and 26 years of age had a regular health care
provider. Ninety-one percent had heard of the HP virus, 86% heard of the HPV vaccination
while only 9% had a least one dose of the vaccine. The researchers used multivariate logistic
regression to examine predictors of HPV vaccination. Separate models were used for 13-17 year
olds and 18-26 year olds. The women between the ages of 18 and 26 years of age that were most
likely to receive at least one dose of the vaccine were the women that believed the vaccine
protected against cervical cancer (84% vs. 54%) or those who accurately believed that condom
use did not provide full protection against HPV (98% vs. 80%). Only 8% of respondents were
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correct in their knowledge that a normal Pap smear does not mean the HPV infection is not
present. Encouragingly, only 8% of women believed that the vaccine did not negate the need for
Pap smears. Barriers to adoption of the vaccine included a lack of first sexual contact, cost, and
having a regular healthcare provider, all of which were found to be statistically significant.
There was no significant association found between races, income, or geographic regions of
residence within the United States. Age and education were excluded due to collinear
association. The researchers believed that even in the presence of risk factors along with correct
beliefs regarding HPV, vaccine uptake are low. This leads them to point to increased education
of both at risk women and health care providers as possible means to improve vaccine adoption
and compliance.
In a survey study of 18-26 year old diverse community college students (n=178) in
central Los Angeles, California researchers found that those who received the HPV vaccine were
typically younger, had a health-related major, felt that the vaccine was safe, had lower
perceptions that the HPV severity, and perceived that the vaccine was socially accepted
(Marchand, et al., 2012). The survey instrument used by Marchand et al. (2012) was based on
the Health Behavior Framework which affirms multiple influences on health behavior.
Demographic information, HPV awareness and knowledge, perceived vulnerability, severity,
vaccine awareness, beliefs, and vaccine uptake, social norms, provider recommendation, and
health care satisfaction and trust, access to health care, sexual behavior, and finally motherdaughter communication were all evaluated in this study. The majority of the student population
was Latino (59%) and African American (32%) and most had heard of HPV (80%) and the
vaccine (70%). The vaccination rate for HPV was 25% among this sample. Controlling for
demographic variables, the researchers performed a multivariate regression with perceived
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severity, vaccination safety, and social approval. Doctor recommendations were excluded in the
model, since 100% of the vaccinated women reported having a doctor’s recommendation. Those
who rated HPV severity lower, vaccine safety high, and perceived higher social acceptability
were more likely to receive the HPV vaccination. Marchand et al. (2012) cites national data
suggesting the uptake of the HPV vaccine in Latina and Black women is lower than among white
women, but with only two white women in the sample the researcher was unable to make that
comparison. The authors stressed that provider recommendation was a strong factor in HPV
vaccine uptake. As in previous research, emphasis on provider education was mentioned along
with addressing an increase in education of college women that emphasizes vaccine safety,
negative beliefs, and accurate information to increase vaccine uptake (Marchand, et al., 2012).
In the 2010 study by Licht et al the researchers used a descriptive analysis, including chisquare tests and multivariate logistic regression, to examine the relationship between the
dependent variable of “HPV vaccination” and covariates. Demographics (age, university A and
B, race, and religion) were explored to determine associations and vaccination rates. Knowledge
items related to HPV and the HPV vaccination along with the perceived risk of acquiring or
transmitting HPV were also placed in a multiple regression model. The sample was 406 female
students between the ages of 18-26 recruited from two universities. Forty-three percent had at
least one dose of the vaccine. Eighteen-year-olds were four times more likely to receive the
vaccine compared to women 19 to 26 years old. Women who knew that HPV caused genital
warts were almost twice as likely to receive the vaccine. White women (47.2%) were more
likely to be vaccinated compared to black (26.3%) or Asian (28.6%) women. After adjusting for
demographic characteristics, HPV knowledge and perceived risk scores were not predictive of
HPV vaccination. It was interesting to note that the author suggested that the 18-year-olds were
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more likely to receive the HPV vaccine since they had probable contact with a health care
provider prior to college matriculation, because mandatory vaccinations are often required for
college admissions. The need to address provider patient education as a vehicle for increased
HPV vaccination uptake was emphasized (Licht, et al., 2010).
The American Public Health Association (2010) at an annual conference reported that
41% of college women were vaccinated for HPV. In addition to a lack of knowledge concerning
HPV, vaccine safety, costs, and future toxicity are barriers to vaccination. Perceptions, beliefs
and barriers have been explored in connection with HPV and its prevention (Hernandez, 2009).
College women may also benefit from the HPV vaccine; HPV is a transient virus and it often
clears the body within two years, so without target vaccination of these women its benefits may
not be realized. College-age women are at the most risk for HPV exposure. Their lack of
knowledge and low vaccination rates need to be explored in greater detail. Breaking down male
and female populations by race and socioeconomic status would give even greater insight into
the appropriate health promotion techniques needed (Caron, et al., 2009). Identifying specific
groups of women and addressing their needs could allow for targeted health promotion activities.
Policy Implications
Cervical cancer screening with the Pap smear test reduces the death rate from cervical
cancer nearly 80% in Western countries (CDC, 2008). There is the potential to further reduce
the mortality rates of cervical cancer with mass vaccination for HPV. The vaccination of groups
of women of lower socioeconomic status who are less likely to receive annual Pap smears would
be beneficial if they receive the series before their first sexual contact. Women could benefit
from education concerning the benefits of HPV vaccine. Education, either by healthcare
providers or health promotion advocates, could result in decreased mortality from cervical
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cancer. A prime example of the efficacy of this approach is the increased awareness, diagnosis,
and decreased mortality from breast cancer due to education and overall public awareness
(Daley, et al., 2012, Raffle, 2007).
College-age women are classified as a “catch up group” when it comes to HPV
vaccination programs. Current and future HPV vaccination programs target preadolescent and
adolescent girls while the 18- to 26-year-olds have the potential to be under-vaccinated and
therefore suffer disproportionately from cervical cancer. Lack of knowledge regarding HPV and
the consequences of infection affect the female college age population (Bandik, et al. 2011,
Lambert, 2001, Yacobi, 1999, Kim, et al., 2008). College student health organizations
traditionally have limited funding and have to be selective in their services and outreach
programs. Future policy may dictate that preadolescent and adolescent girls’ parents are
encouraged or mandated to have their daughters vaccinated for HPV. However, the college-age
“catch up group” may need to be targeted. Since college-age women can independently make
health care choices, they may need to be educated and encouraged to receive the HPV vaccine
(Daley, et al., 2012, Kim, et al., 2008, Raffle, 2007).
The cost of HPV-related cancer is estimated at $4.6 billion a year, and $8 billion for
HPV-related diseases. Uptake of the vaccine in the United States has been defined as less than
optimal by the President’s Cancer Panel in 2012. Besides the positive impact on cervical cancer
rates, oropharyngeal cancer could also be prevented in men. Australia has been able to elevate
HPV vaccination rates by targeted programs, and a decreased incidence of genital wart cases has
been reported (NIH, President’s Cancer Panel (HPV), 2012). There are differences in uptake
among socioeconomic groups. Physicians can also be a barrier to HPV vaccination. It has been
reported that some physicians are reluctant to discuss the uncomfortable subject of protection
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from a sexually transmitted disease and some practices do not stock or offer the vaccine series
due to lower reimbursements (Keating, et al., 2008).
The economic impact of HPV vaccination also has been investigated. In a 2008 study,
researchers used epidemiological and demographic data to demonstrate the cost-effectiveness
ratio of the HPV vaccine as compared with current Pap smear screening practices. This study
was done with the assumption of permanent immunity. The researchers demonstrated the
increased cost-effectiveness ratio for a 12-year-old girl was $43,600 per quality-adjusted lifeyear (QALY), with the ratio increasing to $120,000 per QALY for a 21-year-old. The dramatic
increase in cost for the 21-year-old showed that it is less cost-effective to include an HPV
vaccination program for these women compared to screening with Pap smears alone.
Government and private organizations may find that if a vaccination program limits the QALY
to less than $50,000 it may be economically positive; but the dramatic increase in the ratio for
the college-age group may be less desirable (Kim, et al., 2008). This limited study and other
similar studies have not reached a consensus on the cost effectiveness of the HPV vaccine (Kim,
et al., 2008). The measure of cost-effectiveness in college-age women may be difficult since
there is a dramatic increase in the number of women who have had sexual intercourse, and
baseline knowledge of these women’s sexual practices can be multi-factorial. Due to recently
approved national legislation, Affordable Care Act 2010, mandating the availability of
preventive medicine for all Americans, the HPV vaccine may be included in a preventive health
formulary. Young women may find that the cost of HPV vaccination will be covered under the
new legislation.
The Affordable Care Act, which was signed into law in March 2010 by President Barack
Obama, has a goal of expanding preventive health services and reducing health disparities. The
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development of the Community Preventive Services Task Force will make preventive health
service a priority. Included in this is expanded care for women, including vaccination. The Act
also includes increased funding to expand Public Health Services, and calls for the assembly of a
non-profit Patient-centered Outcomes Research Institute, a non-profit agency which would focus
on health outcomes and clinical effectiveness. A Task Force on Preventive Services and
Community Preventive Services will aid in the development of prevention services that are
recommended based on research evidence. HPV vaccination dissemination among the catch-up
group of women needs to be explored; not only for vaccine effectiveness, but also for barriers
women may face in obtaining the vaccination series.
It also is worth noting that the President’s Cancer Panel (2012) has singled out increasing
HPV vaccination rates as a priority. The panel meets four times a year, as dictated by the Public
Health Service Act, meetings are open to the public and findings are posted on the National
Cancer Institute website. At a September 2012 meeting participants agreed that examination of
the barriers to HPV vaccination was important to increase vaccine acceptability. Policies that
determine price, access, and availability need to be created or changed, according to the panel.
Other topics discussed in the panel were program initiatives, financing, development, and
implementation, and lessons learned from other countries (NIH, The President’s Cancer Panel,
2012). The United States has an increasingly heterogeneous population, thus multiple strategies
to increase HPV vaccination uptake may be needed. September 2012 HPV Committee meeting
summery is available in the Appendix B.
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Conclusion
HPV is the most common yet arguably the most overlooked STD. Genital warts are the
most frequent symptom of HPV, but its worst outcome means that some infected women will
develop cervical cancer later in life. The women at the greatest risk for HPV are in their early
twenties; they are no longer completely guided by their parents when making health care choices
and relying on them for knowledge may prove to be difficult. The use of Pap smears, long a part
of women’s personal health routines, is accepted by college-age women, while the relatively
more recent HPV vaccine is not as widely accepted. Both the Pap smear and the HPV vaccine
serve to decrease the death rate due to cervical cancer. Pap smears can be utilized yearly to
detect abnormal cells on the cervix; while the HPV vaccine is useful before HPV exposure, its
protection rates following intercourse are not clear. The current generation of college women
may not have been afforded the opportunity to receive the three-course vaccination series as
minors. College age women are at risk of HPV because of increased sexual activity and the
number of partners they have. HPV may affect women more adversely, but men transmit the
virus and may benefit from targeted education.
Employing survey data from a database with a heterogeneous female college student
population can be useful to explore the HPV vaccination rates and barriers to receiving the
vaccine. Current studies point to a general lack of knowledge, but these previous studies are
concentrated in homogeneous student populations. There is limited research into the success
rates of programs that use education to increase HPV vaccination rates in college women, as well
as whether these women seek out and/or are offered information regarding HPV vaccination.
The greatest benefit for women is to receive HPV vaccinations before their first sexual
encounter, but without targeted education and vaccination, no benefit will be realized. Policy
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makers need direction when making policy and funding decisions regarding HPV education and
vaccination.
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Chapter 3
Methods
Introduction
This chapter includes the research problem, research question, hypotheses, research design, and
population of interest (unit of analysis), source of data, survey instrument, dependent variable,
independent variables, and data analysis.
Research Problem
The HPV vaccine has the potential to further decrease the development of cervical cancer
in women between the ages of 18-26. This group of women may suffer disproportionately from
cervical cancer compared to adolescent girls who received the vaccine. For health policy makers
there is a need to identify potential barriers, including demographic barriers, to vaccination if
increased HPV vaccination in women age 18-26 is desired.
Research Question
Within the parameters of data from the American College Health Association-National College
Health Assessment, what factors can be identified that affect HPV vaccination rates in college
women 18-26 years old?
Null Hypotheses
1. H0: There is no difference in demographic characteristics between women who receive
the HPV vaccine and those who do not.
2. H0: There is no difference in HPV vaccination rates between college women who receive
information regarding STDs and those who do not.
3. H0: There is no difference in HPV vaccination rates in college women who receive yearly
gynecological exams and those who do not.
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4. H0: There is no difference in HPV vaccination rates among college women who receive
the Hepatitis B vaccine(s) and those who do not.
5. H0: There is no difference in HPV vaccination rates among college women who receive
the influenza vaccine and those who do not.
6. H0: There is no difference in HPV vaccination rates of college women who have
insurance and those who do not.
7. H0: There is no difference in HPV vaccination rates in women who have multiple sexual
partners and those who do not.
8. H0: There is no difference in the likelihood of HPV vaccination amongst the predictor
variables in the binary logistic regression.
Available data for analyses
A secondary analysis of American College Health Association’s (ACHA) National College
Health Assessment (NCHAII) was done with emphasis on questions dealing with demographics,
vaccination rates, healthcare behaviors, and STD information gathering of college women ages
18-26. The sample size for this analysis was 68,193 college women between the ages of 18-26.
Women excluded from the analysis were those who did not identify race or identified more than
one racial category.
Unit of Analysis
The unit of analysis was women enrolled in college between the ages 18-26. This
population was subdivided by race. Women in this age group are classified as the “catch-up
group” by the Centers for Disease Control with regards to the HPV vaccine. The women
completed the survey in either the fall or spring 2008, fall or spring 2009, or fall 2010. Women
who were not between the ages of 18-26 and those who did not identify their race, excluded their
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race, or identified more than one racial category were disqualified from the analysis. The total of
number of participating institutions was 253. The National Center of Educational Statistics
reported that in 2010, 57-58% of college students were women. The percentage of college
women by race in the United States is approximately 72.9% white, 10.3% black, 8.8 Hispanic,
7.3% Asian and .8% American Indian (National Center for Educational Statistics, 2013).
Source of the National College Health Assessment
The American College Health Association (ACHA) is a non-profit organization founded
in 1920. The mission of the ACHA is to provide advocacy and leadership for college/university
health. The mission statement of ACHA is “The American College Health Association will
provide advocacy, education, communications, products, and services, as well as promote
research and culturally competent practices to enhance its members' ability to advance the
health of all students and the campus community” (American College Health Association, 2013).
The ACHA membership comprises 800 institutions that are a mix of various sizes of 2and 4-year colleges that are either public or private. There are 2,800 individual memberships
that encompass a diverse collection of health care professionals that include physicians,
physician assistants, nurses, nurse practitioners, mental health providers, health educators,
dietitians, and pharmacists. Corporations and non-profit organizations connected to college
health are sustaining members. The development of the National College Health Assessment
survey by the ACHA provides members with information regarding health trends of college
campuses (American College Health Association, 2013).
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Survey instrument
The American College Health Association-National College Health Assessment (ACHANCHA) is a national survey that has been used by 587 institutions of higher education since its
inception in 2000. Students at each self-selected institution are randomly selected by
classrooms. Individual colleges determine which classrooms will be selected and the percentage
of students surveyed. The survey can be paper based or web based, according to the educational
institution’s preference. No identifying information is gathered, surveys are completely voluntary
and are anonymous, if paper-based, versus confidential if the surveys are web-based. Web-based
surveys use a random number assignment to protect individual student identity and prevent
multiple submissions. Results of the web-based surveys are not released to participating
institutions until identifying emails are removed. Institutions are provided the results of surveys
that pertain to only their college/university. The ACHA-NCHA publishes reference group
executive summaries for spring and fall semesters based on year. Survey security is ensured by
ACHA-NCHA via the use of a firewall and files are backed up every 24 hours. If participating
institutions require National Institutes of Health (NIH) certificates of confidentially then the
institution must apply directly to the NIH. Paper based surveys have to be scanned into the
ACHA-NCHA data base. Students can or cannot be offered incentives, according to the
preference of the participating college (American College Health Association-National College
Health Assessment, 2013).
Randomly selected students are sent a welcome letter inviting them to participate in the
survey. Consent to participate in the survey is implied when the student opens the survey. Email lists are provided by participating colleges and the ACHA-NCHA randomly selects students
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for participation. Individual institutions determine the best way to technically handle e-mail
address access. Reminder e-mails letters are sent to non-responders. The ACHA-NCHA
recommends that institutions send up to 3 reminder e-mails with each reminder sent every 4-7
days. Labeling of the reminder e-mails can include statements like “last chance”. The exact date
that reminder e-mails are sent is coordinated with participating institutions. The ACHA-NCHA
also recommends that the survey stay open for no more than 2 to 3 weeks. Colleges have to
determine if Internal Review Board approval is needed (American College Health AssociationNational College Health Assessment, 2013).
The cost of the survey depends on the institution’s membership status with the ACHA.
The approximate cost to member institutions is 20 cents per web-based survey and 40 cents per
paper-based survey. For non-members the cost per survey was 40 cents per web-based survey
and 75 cents per paper based surveys. Non-responder emails were 10 cents per reminder for
members and 20 cents for non-members. There were additional costs associated with the addition
of questions desired by specific institutions as well as specialized statistical analysis (ACHANCHA, 2013). An informational brochure is used to recruit institutional members and is
included in Appendix C.
The 65-question survey takes an average of 30 minutes to complete and the depth of the
survey is extensive. Demographic, preventive health questions (including vaccinations), along
with a wide range of questions assessing alcohol, tobacco and drug use, sexual health and safety,
weight management and nutrition, violent encounters and personal safety, and mental health of
the students. The ACHA-NCHA codes completed surveys by geographic location. Geographic
location is defined by the US Census Bureau (US Census Bureau, 2013). All surveys are kept
confidential and the descriptive data is given to each educational institution. Data is then
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compiled by the American College Health Association-National College Health Assessment to
obtain descriptive statistics for all participating institutions. The surveyors acknowledge that the
information is not to be generalized to all universities since universities are self-selected. This
survey is administered once a year at the participating institutions in the fall or the spring
semester based on the colleges’ preference (ACHA-NCHA, 2013).
The National College Health Assessment II (NCHAII) was a revision of the previous
surveys and was used in 28 institutions from 2000 through the spring of 2008. The survey was
revised in the fall of 2008 to include questions on HPV, the flu vaccine and mental health. The
secondary analysis for this study will utilize data from the following semesters - 2008 (fall),
2009 (spring and fall), and 2010 (fall). The total number of institutions that participated in the
survey is 253. The data from fall 2010 and years 2011 and 2012 are not available for outside
research. Access was granted in December 2011 by the American College Health
Association/National College Health Assessment for use in this dissertation, an approval letter
and guidelines in Appendix D. This study will select questions used in the secondary data
analysis that are directly and indirectly related to HPV vaccination.
Reliability and validity analysis
Reliability measurement in survey data ensures that there was consistency in the
measures. Content and construct validity was essential to verify that the survey measures what
was intended. The National College Health Analysis Survey was evaluated for reliability and
validity by pilot testing and comparing survey items with previous national survey studies. The
American College Health Association/National College Health Analysis pilot tested the initial
survey from 1998 to 1999. National survey studies used for analysis included the National
College Health 1995 Risk Behavior Survey (CDC), Harvard School of Public Health 1999
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College Alcohol Study, and United States Department of Justice: The National College Women
Sexual Victimization Study 2000 (American College Health Association-National College
Health Assessment, 2013).
According to the ACHA-NCHA (2012) reliability was tested using Chronbach’s alpha
with scores ranging from 0.4 to 0.9. When the National College Health Assessment was
compared with the aforementioned national studies similar alpha coefficients were demonstrated
across the data. Testing of the survey’s construct validity was done with Pearson correlations
which indicated that the National College Health Assessment had construct validity. The
measurement of validity was done using logistic regression with the main coefficient being the
odds ratio. In comparison to the Harvard School of Public Health 1999 College Alcohol Study,
the National College Health Assessment was found to have measurement validity (National
College Health Assessment ACHA-NCHA Reliability and Validity Measures, 2013).
Data analysis
Descriptive, bivariate analysis, binary logistic regression was the method of analysis.
Bivariate analysis was used to evaluate the relationship between variables. Predictor variables
with statistically significant relationships with the dependent variable, HPV vaccination, were
included in the logistic regression. Vaccine receipt is defined as those who received a least one
dose of the vaccination series. Descriptive statistics was employed to characterize the sample as
a whole and detect differences between those who have received the HPV vaccine and those who
did not. Descriptive analysis reporting will be done by overall population, race and geographic
location. Bivariate correlation was used to determine the relationships between the variables; a
cut off of .7 was used. Chi-square analysis was utilized to compare means of the predictor
variables race, geographic region, receiving STD information, receiving a gynecological exam in
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the last 12 months, Hepatitis B vaccination, influenza vaccination, and primary source of health
insurance with a statistical significance of p<.05. See table 2 listing reported rates.
Table 3.1
Reported rates
HPV Vaccination Ratesa
-HPV by race
-HPV vaccination by geographic location
Healthcare behavior ratesa
-Gynecological exam in the past 12 months by race
-Gynecological exam in the past 12 months by geographic location
-Hepatitis B vaccination by race
-Hepatitis B vaccination by geographic location
-Influenza vaccination by race
-Influenza vaccination by geographic location
-Health Insurance Status by race
-Health Insurance Status by geographic location
Information gathering behaviors ratesa
-Received Information Regarding Sexually Transmitted Disease by Race
-Received Information Regarding Sexually Transmitted Disease by Geographic
Location
Age and Number of sexual partners in the past 12 months
- ageb
- sexual partnersb
a
percentages and chi-square analysis
b
mean(SD) provided

Binary logistic regression was employed with the dependent variable being “Have you
received the HPV vaccine” which is dichotomous (yes/no). Independent variables in the binary
logistic analysis will include: race, geographic region of the institution, receiving STD
information, having a gynecological exam in the past 12 months, receiving the Hepatitis B
vaccine series, receiving the flu vaccine, primary source of insurance, age, and number of sexual
partners in the past 12 months. See table 3 for dependent and independent variables included in
the binary regression.
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Table 3.2
Variables included in the binary logistic regression analysis
Dependent Variable
HPV Vaccination
Independent Variables
-Race
White/non-Hispanic
Black/non-Hispanic
Hispanic/Latino
Asian/Pacific Islander
Native American/Native Alaskan/Native Hawaiian
Biracial/Multiracial
Other
-Geographic Region
Northeast
Midwest
South
West
-Received Information Regarding Sexually Transmitted Diseases
-Received Gynecological exam in past 12 months
-Past Hepatitis B Vaccination
-Past influenza Vaccination
-Primary Source of Insurance
College/university plan
Parents’ plan
Another plan
No health insurance
-Age in years
-Number of Sexual Partners in the Past 12 Months

Categorical independent variables included: race (1=White/non-Hispanic, 2=Black/nonHispanic, 3=Hispanic/Latino, 4=Asian/Pacific Islander, 5=American Indian/Alaskan
Native/Native Hawaiian, 6=Biracial/Multiracial, 7=Other), geographic location of the
educational institution (coded 1=Northeast, 2=Midwest, 3=South, 4=West) as defined by the US
Census Bureau (Appendix E), receiving STD information from the respondents college or
university (yes/no), having a gynecological exam in the past 12 months (yes/no), Hepatitis B
vaccination (yes/no), influenza vaccination (yes/no), and source of insurance
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(1=college/university plan, 2=parents’ plan, 3=another plan, 4=no health insurance). Continuous
independent variables included age and number of sexual partners within the past 12 months.
IBM SPSS Statistic 20 computer software will be used to complete the data analysis.
Brief summary selection of independent variables
Race, age, and geographic location
The majority of vaccination and disease burden rates are published by gender, race,
and/or age by federal agencies such as the Centers for Disease Control. Being a member of an
ethic minority has been linked to decreased cervical cancer screening (McAlearney, et al., 2010,
Rodriques, et al., 2005, Swan, et al., 2003, Solomon, et al., 2007).
rate of cervical cancer screening (Rodriquez, et al., 2005).

Hispanic women have a low

Ethnic diversity is considered a

barrier to HPV vaccination (Herzog, et al., 2008). However, Caskey, et al., (2009) demonstrated
that race was not a predictor of vaccination. Black women had a lower awareness and knowledge
of the HPV vaccine compared to white women (Crates, et al., 2009). Caskey et al. (2009)
reported that white college women were more likely to be vaccinated compared to black or Asian
women. Brewer et al. (2007) did not demonstrate that race was a predictor of HPV vaccine
uptake. In addition, the CDC reported that cervical cancer rates are higher among blacks and
Hispanics compared to whites (CDC, 2012). There are contradictory findings concerning race
and HPV vaccine uptake in college women.
Geographic location is referenced in several studies of individual institutions (Bendik, et
al., 2011, Caron, et al., 2009, D’Urso, et al., 2007). Providing HPV vaccination rates by race and
geographic location may be informative for future researchers.
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Have you received information on Sexually transmitted disease/infection (STD/I) prevention
from your college or university?
A barrier to HPV vaccination is lack of knowledge about the virus and its association
with the development of genital warts and various cancers (Brewer, et al., 2007, Giambi, et al.,
2011, Rosenthanl, et al., 2011). College students are at high risk for HPV exposure but do not
believe that they are at risk (Bendik. et al., 2011, Yacobi, et al., 1999, Val-Smith, et al., 1992).
Burak, et al. (2011) demonstrated that 80% of college women believed that they were not
susceptible to sexually transmitted diseases when, in fact, they were at risk. Cognitive
understanding of HPV is an important factor in understanding the dangers of the virus (Kahn, et
al., 2007). Brief educational intervention was also shown to increase knowledge of HPV
(Lambert, 2001). Women who knew the cause of genital warts were more likely to receive the
vaccine (Licht, et al., 2009).
Gynecological exam in the past 12 Months
Physician recommendation is strongly related to HPV vaccination (Bendik, et al., 2011).
Vaccine acceptability was higher when individuals believed that their physician would
recommend it (Brewer, et al., 2007). One study of professional women found that 71.6% of
respondents reported that their physicians did not discuss HPV with them (Cermak, et al., 2010).
Keane, et al. (2005) cited that doctors and nurses are sources of credible information regarding
vaccination. Marchand et al, (2012) emphasized the need for provider education to increase HPV
vaccine uptake in college age women. Gynecologists are a source of care for sexual health of
college women and therefore, a potential source of information regarding HPV.
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Received Hepatitis B vaccination
Hepatitis B is a mandatory vaccination for admission to many publically funded
universities. The vaccine is given in a series of three injections, as is the HPV vaccine. The
Centers for Disease Control and Prevention (2008) reports that uptake of the Hepatitis B vaccine
92.3%, which can serve as a possible contrast.
Received Influenza vaccination
Influenza and HPV vaccination are similar in that they are both voluntary vaccinations
that protect against future infection. Influenza vaccination rates in college students have also
been explained by the Health Belief Model. Increased susceptibility and morbidity of the flu
increased the intention to receive the vaccine (Teiter-Regev, et al., 2011). Arguably, the flu
vaccine receives more media coverage and physician recommendations which can also serve as a
contrast to the HPV vaccine.
Primary source of health insurance
Socioeconomic status and lack of health insurance is linked to decreased cervical cancer
screening (Kessel, et al., 2012, Rodriques, et al., 2005). Higher HPV vaccine up-take was
associated with having health insurance (Kassels, et al., 2012). Women in a poor rural area of
Ohio were more likely to perceive lack of insurance as a barrier to cervical cancer screening
(McAlearney, et al., 2010). Hispanic women were found to have higher cancer screening rates
when they had health insurance (Zambrana, et al., 1999).

In a low income setting, Kahn, et al.

(2008) reported that insurance coverage was significant in a logistic regression model.
Number of sexual partners in the past 12 months
Jones, et al. (2008) linked an increase in the number of sexual partners with increased
intent to receive the HPV vaccine. A potential barrier to adoption of the HPV vaccine is lack of
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first sexual contact (Caskey, et al., 2009). The belief that virginity negates the need for
vaccination may stop women from seeking the vaccine. Caron, et al (2009) in a limited study
found that 56.5% of sexually active women were aware of HPV but did not think they were at
risk for infection.
Conclusion
The dependent variable in this analysis was receiving the HPV vaccine, the purpose of
the chosen methodology was to determine which independent variables were statistically
significance. The independent variables in the analysis were race, geographic location, receiving
STD information, gynecological exams in the past 12 months, receiving the Hepatitis B vaccine
and influenza vaccine, age, and number of sexual partners.
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CHAPTER 4
RESULTS

Introduction
The focal point of this chapter is to present a synopsis of the findings. Female students
included in the analysis were between the ages of 18-26 who participated in the ACHA-NCHA
survey during the following semesters: fall 2008, spring and fall 2009 and fall 2010. The 253
institutions that administered the survey were not identified. The Standards for the
Classification of Federal Data on Race and Ethnicity (1997) calls for racial categories that
include White/non-Hispanic, Black/non-Hispanic, Hispanic/Latino, Asian/South Pacific
Islanders, and Native American/Alaskan Native/Hawaiian Native. The federal government is
supportive of the Biracial/Multiracial category. This analysis endeavored to adhere to these racial
classification guidelines.
The ACHA-NCHA survey utilized the federally recommended racial categories.
Therefore, these categories were maintained in this study. The racial category “other” was
maintained, this category is un-defined making it problematic to describe to any existing data.
Exclusion of respondents that indicated only Biracial/Multiracial or “other” was not done. There
is a growing recognition in the field of public health that because of the growing diversity of the
United States and the use of self-identification in surveys more respondents in the future may
classify themselves in this manner and exclusion of these groups may place them at a
disadvantage, or fail to show trends in these racial categories (Mays, et al., 2003). The use of undefinable racial categories presents researchers with some major challenges, clear definition of
racial categories is important to studies in which epidemiology (the distribution and determinants
of health related states and trends) and race is examined. When determining health trends,
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setting policy and evaluating health related programs it is imperative to ensure that demographic
characteristics are unambiguous as possible. When asked for race, respondents of the ACHANCHA were instructed to mark “all that apply”, which failed to be mutually exclusive. As a
result, assigning respondents a racial category who identified themselves in more than one racial
category was complicated due to the lack of a sound allocation process (Liebler, C., et al., 2008,
Mays, V., 2003). It was decided, therefore, that it was important to limit the subjective bias of
the researcher. Subsequently, those respondents were excluded along with respondents that failed
to identify any race (n=20,992). Since the CDC reports vaccination and health behavior rates by
racial category, it was decided that that epidemiological format be maintained in the reporting of
statistics. Survey respondents were also excluded if they did not answer the HPV vaccination
status question or they answered that they did not know if they received the vaccine (n=2,120).
After the qualifying standards were set (i.e. female students between the ages of 18-26 who
identified a single racial category and who reported that they knew their HPV vaccine status) the
total sample in this analysis was N=68,193. The average respondent age was 20.5 years and
85.8% of students reported that they had attended college/university four years or less.
Furthermore, 95.5% of students were enrolled full time.
Demographics by race
The racial demographics of the respondents were White/non-Hispanic (76%), Black/nonHispanic (7%), Hispanic/Latino (6%), Asian/Pacific Islander (9%), American Indian/Alaskan
Native/Native Hawaiian (1%), Biracial/Multiracial (0.1%), and other (1%). The
Biracial/Multiracial category is possibly underrepresented with only 40 respondents. Table 3.1
displays respondent demographics by race and mean age for each racial category.
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Table 4.1
Demographics (n=68193)
Race
White/non-Hispanic
Black/non-Hispanic
Hispanic/Latino
Asian/Pacific Islander
American Indian/Alaskan Native/Native
Hawaiian
Biracial/Multiracial
Other
a
percentage do not equal 100% due to rounding

Cohen, T.F.

n (%)a

M(SD)

51,826 (76)
4,400 (7)
4,134 (6)
6,102 (9)

20(1.3)
20(2.1)
20(2.2)
21(2.2)

795 (1)
40 (.1)
896 (1)

21(1.8)
19(1.7)
21(2.0)

Demographics by geographic location
Geographically, the Northeast region had the highest percentage of respondents (30%)
followed by, the Southern (29%), Midwest (20%), and Western (20%) regions. The average age
of respondents was similar, ranging from 20-21 years of age. Table 3.2 provides the number of
respondents within each region along with their mean age.

Table 4.2
Number of women by geographic region
(n=68042)a
Northeast
Midwest
South
West
a
n=151(0 .002%) cases not classified by region
note: % does not equal 100% due to rounding

n (% within total
population)
20,579 (30)
13,875 (20)
19,972 (29)
13,616 (20)
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mean age (SD)
20(2)
21(2)
20(2)
21(2)
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HPV vaccination rates by race
In this analysis, 33,554 women (49%) received the HPV vaccine. The rate of HPV
vaccination varies by racial category. White/non-Hispanic women had an HPV vaccination rate
of 51%. The vaccination rate among American Indian/Alaskan Native/Native Hawaiian women
was 47% while Hispanic/Latino women had a vaccination rate of 46%. The rate of vaccination
among Black/non-Hispanic women and Asian/Pacific Islander women were 44% and 40%,
respectively. Biracial/Multiracial women had a vaccination rate of 60%, which should be
viewed with caution given the low sample size (n=40). Women who identified themselves as
“other” had the lowest vaccination rate (38%). A chi-square analysis was performed to
determine whether statistically significant differences in HPV vaccination rates existed between
racial categories. It should be noted that due to the large sample size it was expected that chisquare analysis would yield statistically significant results. In fact, the distribution of HPV
vaccination rates between racial groups proved to be statistically significant ([X2(6, N=68,193)
=398.114, p=000]). Table 3.3 lists HPV vaccination rates by racial category.

Table 4.3
Women who received the HPV vaccine by race*(n=68193)
White/non-Hispanic
Black/non-Hispanic
Hispanic/Latino
Asian/Pacific Islander
American Indian/Alaskan Native/Native Hawaiian
Biracial/Multiracial
Other
*p=.000, differences in vaccination rates between racial categories proved
significant
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n (% within race)
26,598(51)
1,933(44)
1,910(46)
2,458(40)
377(47)
24(60)
341(38)

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

HPV vaccination by geographic region
HPV vaccination rates were the highest in the Northeast region (55%). The rate of
vaccination in the Southern, Midwest and Western regions were, respectively, 49%, 45% and
45%. A chi-square analysis was performed to investigate whether the HPV vaccination rates
were statistical significance differences between the geographic regions. The distribution of HPV
vaccination rates between geographic regions was statistically significant ([X2(3, N=68042)
=435.752, p=000]). Table 4.4 demonstrates HPV vaccination rates within the four geographic
regions.

Table 4.4
HPV vaccination rates by geographic region* (n=68042)a
Northeast
Midwest
South
West
a
missing cases excluded

n(%)
11,276(55)
6,295(45)
9,858(49)
6,125(45)

*p=.000, differences in vaccination rates between geographic regions proved significant

STD information gathering
The independent variable “have you received information on sexually transmitted
disease/infection prevention from your college or university” is a dichotomous (yes/no) variable.
55% (n=36996) of women received information regarding STD’s. Black/non-Hispanic women
had the highest rate of receiving STD information from their college/university (65%).
Hispanic/Latino women and those who identified themselves as “other” reported receiving STD
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information at a rate of 56%. Fifty four percent of White/non-Hispanic and Asian/Pacific
Islanders women reported receiving STD information. American Indian/Alaskan Native/Native
Hawaiian women had a HPV vaccination rate of 50%. Finally, it was demonstrated that 66% of
Biracial/Multiracial women received STD information which should be regarded with caution
given the small sample size of that category.
In the Northeast region, 58% of respondents reported receiving STD information, while
57% of Southern region respondents reported receiving STD information. 53% of women in the
Midwest region reported receiving STD information and only 47% of Western region
respondents reported having received STD information. STD information gathering within racial
category and geographic region is demonstrated in Table 3.5. .

Table 4.5
Received STD information (information gathering)
Race
n(% within race)
White/non-Hispanic
27,853(54)
Black/non-Hispanic
2,682(65)
Hispanic/Latino
2,294(56)
Asian/Pacific Islander
3,254(54)
American Indian/Alaskan Native/Native
Hawaiian
395(50)
Biracial/Multiracial
24(66)
other
494(56)
Geographic region
Northeast
Midwest
South
West

n(%within region )
11,934(58)
7,352(53)
11,247(57)
6,363(47)
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Overall, 52% (n=19,239) of students who received the HPV vaccine received STD
information whereas 46% (n=14,027) of women who received the HPV vaccine did not receive
STD information.

A chi-square analysis was used to determine if there was statistical

difference between HPV vaccination rates and the rate of receiving STD information. A
statistical significance between HPV vaccination and receiving STD information was
demonstrated ([X2(1, N=67,420) =232.332, p=.000]) and is presented in Figure 3.1.

Fiqure 4.1
Percentage of respondents that received HPV vaccination when
examining receiving and not receiving STD information
52%

46%

Received STD information (n=36,996)

Did not receive STD information (n=30,424)

Health Behaviors
Health Behaviors in the study include receiving a gynecological exam within 12 months,
receiving the Hepatitis B vaccine, receiving the influenza vaccine, primary source of insurance,
and number of sexual partners. 54% (n=36,961) of women in the analysis reported receiving a
gynecological exam in the past months. 5.5% (n=372) of the women in this study group could
not recall if they had a gynecological exam in the past 12 months. White/non-Hispanic women
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had the highest rate of receiving a gynecological exam (58%) and those women who identified
themselves as “other” had a gynecological exam rates of 55%. American Indian/Alaskan
Native/Native Hawaiian women 54% and 53% of Black/non-Hispanic women had a
gynecological exam in the past 12 months. 44% Hispanic/Latino women received a
gynecological exam in the past 12 months. Women who identified themselves as
Biracial/Multiracial had a rate of gynecological exams in the past 12 months of 43%. Finally,
the racial category with the lowest gynecological exam rate in the past 12 months was
Asian/Pacific Islander women (28%).
The geographic region with the highest rate of gynecological exams is the Midwest
region (60%). The Northeast and Southern regions had gynecological exam rates of 55% and
53%. The region with the lowest gynecological exam rate is the Western region (49%).
It was demonstrated that 55% (n=20,227) of women that had a gynecological exam in the
past 12 months also had the HPV vaccine. On the other hand, 43% (n=13,043) of women who
received the HPV vaccine did not have a routine gynecological exam. Gynecological exam in the
past 12 months is a dichotomous (yes/no) variable. A chi-square analysis was performed to
determine if there were differences in HPV vaccination rates between women who received and
did not receive the gynecological exam in the past 12 months. The difference in HPV vaccine
rates were statistically significant between groups ([X2(1, N=66,355) =969.517, p=.000]).
Gynecological exam status and HPV vaccination rates between groups are shown in figure 3.2.
Table 3.6 lists health behaviors by racial category and geographic region.
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Figure 4.2
Percentage of students that received HPV vaccination by
gynecological exam status
55%
43%

Received gynecological exam in past 12
months (n=36,961)

Did not receive gynecological exam in
past 12 months (n=30,507)

The Hepatitis B vaccine is often mandatory when enrolling in college/university. 92%
(n=62,446) of women in the analysis received the Hepatitis B vaccine. The racial category with
the highest Hepatitis B vaccination was White/non-Hispanic women (93%). Asian/Pacific
Islanders had the lowest Hepatitis B vaccination rate (85%). This independent variable is
dichotomous (yes/no). A chi-square analysis was performed to determine if there was a
difference between the rate of HPV vaccination between women who did and did not receive the
Hepatitis B vaccine, this proved to be statistical significance ([X2(1, N=68,023) =2572.261,
p=.000]). Figure 3.3 demonstrates that 52% of women who received the HPV vaccine received
the Hepatitis B vaccine, while only 17% of women who did not received the Hepatitis B vaccine
received the HPV vaccine.

77

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Figure 4.3
Percentage of respondents that received the HPV vaccine when
examining Hepatitis B vaccination status
52.00%

17.00%

Received Hepatitis B vaccine (n=62,446)

Did not receive Hepatitis B vaccine (n=5,577)

When exploring Hepatitis B vaccination by region the highest rate was within the
Northeast region (93%). The Midwest and Southern region had a vaccination rate of 92%. The
Western region had the lowest Hepatitis B vaccination rate (89%). These high vaccination rates
are reflective of the common practice of mandating the Hepatitis B vaccine for matriculation into
higher learning institutions.
Influenza vaccination rates were considerably smaller than Hepatitis B rates. 37%
(n=25,528) of the sample reported receiving the influenza vaccine. Asian/Pacific Islanders have
the highest influenza vaccination rate (44%). The remaining racial categories have influenza
vaccination rates between 36-38%. The geographic region with the highest influenza vaccination
rates was the Northeastern region (40%). The influenza vaccination rate in the Southern region
was 38% and the Midwestern region 36%. The region with the lowest influenza vaccination rate
was the Western region (34%).
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Women who had both the influenza vaccine and the HPV vaccine was 24% (n=16,458).
This independent variable was dichotomous (yes/no). 64% of the women that did have the
influenza vaccine also had the HPV vaccine. A chi-square analysis was performed to determine
if there was a difference between the rate of HPV vaccination between those who did and those
who did not receive the influenza vaccine. The analysis proved that there was statistical
significance ([1, n=66,355) =3612.285, p<.000]) between the two groups. Figure 3.4
demonstrates the HPV vaccination rates depending on influenza vaccination status.

Figure 4.4
Percentage of respondents that received the HPV vaccine when
examining Influenza vaccination status
64%

40%

Received Influenza vaccine (n=25,528)

Did not receive Influeza vaccine(n=42,456)

The independent variable primary source of insurance is divided into 4 categories:
college/university plan, parents’ plan, another plan, and no insurance. White/non-Hispanic
women had the highest rate of having insurance coverage (96%), and women who identified
themselves as “other” 93%. Ninety-four percent of Asian/Pacific Islanders reported having
health insurance and the category “other” reported a 93% insurance coverage rate. Black/non79
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Hispanic reported having insurance coverage at a rate of 91%, and American Indians/Alaskan
Native/Native Hawaiians 90%. Finally, Hispanic/Latino women had the lowest rate of having
insurance coverage (87%).
The majority of women reported that they were covered by their parents’ insurance
(75%). Those reporting that they were covered by plans provided by institutions of higher
learning were 13%. Seven percent of women reported that they were covered by another source
of insurance. Lastly 5% of students reported that they had no source of health insurance.
Health insurance coverage in all geographic regions was high. The Northeast region had
the highest rate of insurance coverage (98%). In the Midwest region 95% of respondents had
insurance coverage and in the Southern region 94%. The region with the lowest rate of
insurance coverage was the Western region (91%).
It was determined that 1% (n=893) of students had the HPV vaccine did not have
insurance coverage. Conversely 54% of women who were covered by their parents’ insurance
received the HPV vaccine. A chi-square analysis was performed to investigate whether there
were statistically significant differences in HPV vaccination rates between insurance coverage
categories. The analysis determined that there was statistical significance between HPV
vaccination and primary source of insurance ([X2(3, N=68,003) =1954.246, p=.000]). Figure 4.5
shows the HPV vaccination rate per insurance coverage category.
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Figure 4.5
Percentage of respondents who received the HPV vaccine by source of
health insurance
54%

36%

36%
28%

College University Plan Parents' Plan (n=51,148) Another Plan (n=5,033) No Insurance (n=3,173)
(n=8,649)

Number of sexual partners is a continuous variable, the average number of sexual
partners was 1.3(SD=1.8). The mean number of sexual partners by race and geographic region
ranges between .8 and 1.5. Women who report zero sexual partners in the past twelve months
was 30% (n=20,458). Respondents with one to two sexual partners was 53% (n=36,093), three
to four sexual partners 9% (n=6,136), and 7% (n=4,760) reported having more than 5 sexual
partners. The number of respondents that did not answer the question regarding number of sexual
partners was 746. Table 4.6 demonstrates the health behaviors within racial categories and
geographic region.

81

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Table 4.6
Health behaviors

within racial
categories

Insurance
coverage
n(%)

Average
number
of
Sexual
Partners
M(SD)

48,087(93) 19,035(37) 49,753(96)

1.3(1.8)

Gynecological Received
exam within Hepatitis B
12 months
Vaccine
n (%)
n(%)

Received
Influenza
Vaccine
n(%)

White/nonHispanic

30,239(58)

Black/nonHispanic

2,339(53)

3,853(88)

1,623(37)

4,004(91)

1.5(2)

Hispanic/Latino

1,806(44)

3,741(90)

1,580(38)

3,597(87)

1.2(1.6)

Asian/Pacific
Islander

1,726(28)

5,216(85)

2,659(44)

5,736(94)

0.8(1.4)

431(54)

731(92)

289(38)

716(90)

1.3(1.9)

18(43)

36(90)

15(38)

38(95)

1.6(2)

402(55)

782(87)

327(36)

833(93)

1.5(1.9)

American
Indian/Alaskan
Native/Native
Hawaiian
Biracial/Multiracial
other
within geographic
regions
Northeast

n(%)
n(%)
11,333(55) 19,102(93)

n(%)
n(%)
8,193(40) 2,0113(98)

M(SD)
1.3(1.9)

Midwest

8,289(60) 12,703(92)

4,974(36) 13,216(95)

1.3(1.8)

South

10,660(53) 18,344(92)

7,589(38) 18,790(94)

1.3(1.8)

West

6,604(49) 12,170(89)

4,688(34) 12,568(92)

1.2(1.9)
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Correlations
Correlation between variables was analyzed. HPV vaccination and race shows a strong
negative correlation (r (66,699) =-.68, p<.01). The remaining variables show negligible to weak
correlations (+/-.01 to +/-.29). All variables tested significant (p<.01) excluding the correlation
between race and receiving STD information (p=.156). Table 3.7 provides the correlation matrix.

Table 4.7
Correlationa between measures

HPV vaccination
Race
Region
Received STD Information
Gynecological exam in past
12 months
Hepatitis B vaccination
Influenza vaccination

Race

Region

-0.68*

-0.06*
0.071*

Received
STD
Information
0.058*
-0.005
-0.062*

0.118*
-0.14*
-0.048*
0.018*

*p<.01
aTaking

Gynecological
Exam in past
12 Months

into account missing cases N=66701
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Hepatitis B
Vaccination

Influenza
Vaccination

Source of
Health
Insurance

0.192*
-0.069*
-0.036*
0.038*

0.233*
0.028*
-0.034*
0.026*

-0.042*
-0.024*
0.106*
-0.045*

0.054*

0.033*

0.027*

0.115*

-0.021*
-0.029*
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Binary logistic regression model
Log (odds of having a HPV vaccine)=1.88*Race(Black)-.102Race*(Hispanic/Latino).23Race*(Asian/Pacific Islander)-.16Race*(American Indian/Alaskan Native/Native
Hawaiian)+.256Race*(Biracial/Multiracial)-.443Race*(other)-.403Region*(Midwest).266Region*(South)-.202Region*(West)+.049 Received STD information+.661Received
gynecological exam in the past 12 months+1.411Received the Hepatitis B+.937Received the
Influenza vaccine+.315Source of Insurance*(College/University plan)+.613Source of
Insurance*(Parents’ plan)+.316Source of Insurance*(Another plan)-.246 age in
years+.053number of sexual partners where the odds=p/(1-P) and p is the probability
Binary logistic regression results
The binary regression model defines the relationship between the independent variables
(race, geographic region, receiving information regarding STD’s, having a gynecological exam
in the past 12 months, receiving the Hepatitis B vaccine, receiving the influenza vaccine, primary
source of health insurance, age, and number of sexual partners) and the dependent variable,
HPV vaccination. The racial categories Black/non-Hispanic, Hispanic, Asian/Pacific Islander,
American Indian/Alaskan Native/Hawaiian Native, and “Other” all proved significant in
predicting HPV vaccination rates (R2=.156, p<.01). Biracial/Multiracial did not test significant
(p=.467), which is most likely due to the small sample size (n=37). Furthermore, geographic
location significantly predicted HPV vaccination (R2=.156, p<.001). Receiving STD information,
having a gynecological exam within the last 12 months, receiving the Hepatitis B vaccination
and receiving the influenza vaccination were also predictive of HPV vaccination
(R2=.156,p<.001). Insurance coverage was predictive of HPV vaccination (R2=.156, p<.001) as
was age (R2=.156, p<.001). For every one year increment in age there is a .246 decrease in the
log-odds of having received the HPV vaccine. In other words, as age increases the likelihood of
receiving the HPV vaccine decreases. In addition, the number of sexual partners in the past 12
months was significant (R2=.156, p<.001). Every .053 increase in the number of sexual partners
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increases the likelihood of receiving the HPV vaccine. The Hosmer-Lemshow statistic did not
demonstrate goodness of fit X2(8, N=67,110) =18.66, which is not surprising given the large
sample size. Hosmer-Lemshow statistics in sample sizes over 13,000 tend to not demonstrate
goodness of fit. There is debate whether the use of the pseudo-R2 is useful in the analysis of
binary logistic regression, since the measure is rightfully designed to be used in linear regression
analysis. In this study it was decided that using the pseudo-R2 would aid in demonstrating the
explanatory value of the model. Table 4.8 provides the variables in binary regression results.
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Table 4.8
Variables in the equation
Variable

B(SE)

Wald

Sig.

Race
White/non-Hispanic (ref)
Black/non-Hispanic*

-0.295(0.037)

62.963

0.000

Hispanic/Latino**

-0.102(0.037)

7.545

0.006

Asian/Pacific Islander*

-0.23(0.032)

51.079

0.000

American Indian/Alaskan Native/Native Hawaiian***

-0.16(0.079)

4.117

0.042

Biracial/Multiracial

0.256(0.351)

0.529

0.467

Other*

-0.443(0.078)

32.133

0.000

Midwest*

-0.403(0.025)

269.653

0.000

South*

-0.266(0.022)

142.342

0.000

West*

-0.202(0.025)

65.675

0.000

0.049(0.017)

8.013

0.005

0.661(0.018)

1303.057

0.000

1.411(0.039)

1287.652

0.000

0.937(0.018)

2787.88

0.000

College/University plan*

0.315(0.05)

41.064

0.000

Parents' plan*

0.613(0.045)

186.111

0.000

Another plan*

0.361(0.055)

43.675

0.000

a*

Geographic Location
Northeast (ref)

Receiving STD Information
Did not receive(ref)
Did receive*
Gynecologic examination
Did not receive(ref)
Did receive*
Hepatitis B vaccination
Did not receive(ref)
Did receive*
Influenza vaccination
Did not receive(ref)
Did receive*
Source of Insurance
No insurance (ref)

Age in years

-0.246(0.005)

2251.589

0.000

Number of sexual partnersa*

0.053(0.005)

97.835

0.000

Constant
Note: Pseudo R2 Cox & Snell= .156; Nagelkerke= .208, -2
Log likelihood 79874.772, df=18, S.E.=.008,
(ref)=reference category

1.888(0.121)

244.563

a

continuous variable

*p<.001
**p<.01
***p<.05
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The odds-ratios, Exp B, are given with respective 95% confidence intervals. Reference
categories were established to allow for easier interpretation of odds ratios. Examining
vaccination rates determined that White/non-Hispanic women had the highest HPV vaccination
rate (51%). Therefore, White/non-Hispanic women became the reference group in the regression
model. The reference group for region is Northeast since it had the highest HPV vaccination rate
(55%). Receiving STD information is a dichotomous variable and the reference category was
not receiving STD information. Having a gynecological exam in the past 12 months is
dichotomous and the reference category was not having a gynecological exam in the past 12
months. Hepatitis B and influenza vaccination are dichotomous; the reference category for both
is not receiving the vaccine. Primary source of health insurance has four categories,
college/university plan, parents’ plan, another plan, and no insurance. No insurance is the
reference category in the variable which makes interpreting the odds-ratios less difficult.
The odds-ratio demonstrated that White/non-Hispanic women (referent category, OR=1)
have a higher likelihood of receiving the HPV vaccination compared to the following categories:
(Black/ non-Hispanic (OR=.744, 95% CI=.692-.801), Hispanic/Latino (OR=.903, 95% CI=.84.971), Asian/Pacific Islander (OR=.795, 95% CI=.746-.847), American Indian/Alaskan
Native/Native Hawaiian (OR=.852, 95% CI=.73-.995), other (OR=.642, 95% CI=.643-.551).
Using the Northeast as a reference category (OR=1), the Midwestern (OR=.668, 95% CI=.637.701), Southern (OR=.766, 95% CI=.733-.800) and Western (OR=.817, 95% CI=.778-.858)
regions demonstrate a lower likelihood of receiving the HPV vaccine. Receiving STD
information from the college/university increases the likelihood of receiving the HPV vaccine
(OR=1.05, 95% CI=1.015-1.086) as does having a gynecological exam in the past 12 months
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(OR=1.936, 95% CI=1.868-2.007). Receiving the Hepatitis B (OR=4.1, 95% CI=3.796-4.428)
and influenza (OR=2.553, 95% CI=2.465-2.643) vaccines also increases the likelihood of
receiving the HPV vaccine. A primary source of health insurance, college/university plan
(OR=1.371, 95% CI=1.242-1.513), parents’ insurance plan (OR=1.845, 95% CI=1.689-2.016),
or another plan (OR=1.434, 95% CI=1.289-1.596) also increases the likelihood of receiving the
HPV vaccine compared to lacking health insurance (reference category, OR=1). Table 4.9
provides the odds-ratios and 95% confidence intervals as determined by the logistic regression.
Appendix F provides the variable coding, Omnibus Test of Model Coefficients, Model
Summary, Hosmer and Lemeshow Test and Contingency Table, and Classification Table.
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Table 4.9
Odds-ratios with 95% confidence
intervals
Variable
Race
White/non-Hispanic (ref)
Black/non-Hispanic*
Hispanic/Latino**
Asian/Pacific Islander*
American Indian/Alaskan Native/Native Hawaiian***
Biracial/Multiracial
Other*
Geographic Location
Northeast (ref)
Midwest*
South*
West*
Receiving STD Information
Did not receive(ref)
Did receive*
Gynecologic examination
Did not receive(ref)
Did receive*
Hepatitis B vaccination
Did not receive(ref)
Did receive*
Influenza vaccination
Did not receive(ref)
Did receive*
Source of Insurance
No insurance (ref)
College/University plan*
Parents' plan*
Another plan*
*p<.001
**p<.01
***p<.05
Note: reference category
(ref)

89

Cohen, T.F.

OR

95% CI
Lower Upper

1
0.744
0.903
0.795
0.852
1.291
0.642

0.692
0.84
0.746
0.73
0.648
0.551

0.801
0.971
0.847
0.995
2.572
0.748

1
0.668
0.766
0.817

0.637
0.733
0.778

0.701
0.8
0.858

1
1.05

1.01

1.086

1
1.936

1.868

2.007

1
4.1

3.796

4.428

1
2.553

2.465

2.643

1
1.371
1.845
1.434

1.242
1.689
1.289

1.513
2.016
1.596
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Conclusion
The large sample size (N=68,193) provided by the ACHA-NCHA survey allowed the
researcher to examine selected factors that may influence HPV vaccination rates. It was
demonstrated that race was an influencing factor in HPV vaccination rates. There were
variances in the HPV vaccination rates between geographic regions. A higher percentage of
women who received STD information received the HPV vaccine. Engaging in preventive
health behaviors (receiving a gynecological exam in the past 12 months, receiving the Hepatitis
B and influenza vaccine, and having a source of health insurance) was associated with higher
HPV vaccination rates. This was further confirmed by the binary regression model which
demonstrated that engaging in preventive health care behaviors increased the likelihood of
receiving the HPV vaccine. The null hypotheses in this analysis were rejected.
The age of the sample was limited to those defined as the “catch-up” group (18-26 years
old). The binary regression analysis found age to be a significant factor. As age increased the
likelihood of receiving the HPV vaccine decreased. This could be due to the fact that women
over the age of 19 were not exposed to the HPV vaccine recommendation as adolescents. The
regression model also demonstrated that as the number of sexual partners increased so did the
likelihood of receiving the HPV vaccine. This is of concern since there may be a misconception
that it is best to receive the vaccine after engaging in sexual intercourse, while the opposite is
true.
Receiving STD information from one college/university also increased the likelihood of
receiving the HPV vaccine. This should be viewed with caution, since there is no feasible way
to evaluate the educational material students received or even if HPV information was included.
Knowledge of HPV is considered low among the “catch-up” group. Education may prove
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fundamental in the endeavor. This secondary analysis should not be generalized to the entire
female college student population. Colleges and universities that participated in the survey were
self-selected. This analysis also had the limitation of being dependent on self-reporting.
This analysis offers a broad insight into HPV vaccination rates in a large sample of
college women. Exploring barriers to HPV vaccination is useful when making decisions
regarding health promotion activities that may decrease disparities. The model’s low pseudo-R2
of .156 is indicative of the fact that only a limited amount of variables that may affect HPV
vaccination rates were tested. Increasing HPV vaccination rates depends on constructs, as
defined by the Health Belief Model, such as perceived risk, perceived susceptibility, perceived
benefits, and cues to action, which this analysis could not explore.
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Chapter 5
Discussion
Introduction
The focus of this chapter is to discuss the relevance of the analysis. The HPV vaccine has
been shown to be safe and effective in women (Harper, et al., 2004, Goldie, et al., 2011). It is
recommended by the CDC that along with delivery of the HPV vaccine to adolescent girls the
vaccine be administered to women ages 18-26. This recommendation does not include
comprehensive strategies for increased delivery to this group of individuals. Research has shown
that even after sexual contact, women may realize the benefits of the HPV vaccine due to the
unpredictable behavior of the virus (Elbasha, et al., 2005). This analysis explored several factors
that may affect HPV vaccination in college age women. The large sample size (N=68,193)
provided by the American College Health Association-National College Health Assessment
provided this study with greater sensitivity than previous research when examining HPV
vaccination rates and the rates of health behaviors between racial and geographic categories
(Bendik, et al., 2011, Caron, et al., 2009, Jones, et al., 2008, Kahn, et al., 2008, Licht, et al.,
2099, Marchand, et al., 2012). A representative sample of racial categories of female college
students in the United States, excluding Biracial/Multiracial women, was studied. The racial
category that had the strongest probability of being under-represented was Biracial/Multiracial
(n=40). The binary regression analysis finding in that category did not prove to be statistically
significant. The racial category “other” also proves difficult to analyze since there is a lack of
definition of that group and a lack of comparison data.
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The influence of race on HPV vaccination and gynecological exam rates
In this analysis, 49% of college women received the HPV vaccine, which is higher than
the 41% reported by the American Public Health Association in 2012. The ACHA-NCHA survey
did not specify how many doses in the three shot series respondents received. It can only be
assumed that the students in the current analysis had at least one dose of the vaccine. As a result,
a drawback of this analysis is that vaccination series completion rates cannot be provided. The
racial category with the highest reported HPV vaccination rate was White/non-Hispanic women
(51%). Being a member of an ethic minority was described by Herzog, et al. (2008) and Cates et
al. (2009) as a barrier to HPV vaccination. Conversely, Caskey et al. (2009) showed that race
was not an influencing factor. The current study found that there was a statistical significance
(p=.000) between HPV vaccination rates and race, which is not surprising given the large sample
analyzed. Black/non-Hispanic, Hispanic/Latino, Asian/Pacific Islander, American
Indian/Alaskan Native/Native Hawaiian and women who described themselves as “other” had
lower vaccination rates when compared to White/non-Hispanic women. The racial category
Biracial/Multiracial had the highest vaccination rate (60%), but again, the small sample size
should make this finding suspect. In this study, all of the other racial categories (excluding
Biracial/Multiracial) had a lower likelihood of receiving the HPV vaccine when compared to
white women (as determined by the binary logistic regression analysis).
In addition, white women had the highest rate of receiving a gynecological exam in the
past 12 months (58%) and being covered by health insurance (96%). This is consistent with the
CDC report in 2008 that white women had the highest rate of receiving a Pap smear. It is
important to keep in mind that the CDC data concerning Pap smear rates is not limited to women
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between the ages of 18-26. It should be noted that White women have the lowest rate of cervical
cancer in the United States (NIH,SEER Data, 2012).
Hispanic/Latino and American Indian/Alaskan Native/Native Hawaiian women had HPV
vaccination rates of 46% and 47% respectively. Hispanic/Latino women had a lower likelihood
(OR=0.903, 95% CI=0.84-0.971) of receiving the HPV vaccine when compared to White/nonHispanic women and American Indian/Alaskan Native/Native Hawaiian women were also less
likely to receive the HPV vaccine (1.0 vs. OR=0.852, 95% CI=0.73-0.995) compared to
White/non-Hispanic women. The American Cancer Society (2012) reported that
Hispanic/Latino women have a higher mortality rate due to cervical cancer when compared to
white women (3.0 vs. 2.2 per 100,000 women). The United States Department of Health and
Human Services (2012) reports that American Indian women have a higher incidence of cervical
cancer when compared to all other races (2.8 vs. 2.4 women per 100,000). Furthermore, the
mortality rate for this minority is higher when compared to white women (2.3 vs. 4.0 women per
100,000).
American Indian/Alaskan Native/Native Hawaiian women reported a 54% gynecological
exam rate and Hispanic/Latino women had a rate of 44%. In 2008, the CDC reported that
Hispanic/Latino women had a Pap smear rate of 75.4%. It should again be stressed that CDC
data is not limited to women 18-26 years old. The current study demonstrated that 87% of
Hispanic/Latino were covered by health insurance which was the lowest percentage among the
racial categories. It has been demonstrated that lack of health insurance is a predictor of not
having a Pap smear. Therefore, cervical cancers could go undetected in these women
(McAlearney, et al., 2010). A comprehensive national statistic regarding the gynecological exam
rates of American Indian women was not readily available. Past research has shown that
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geographic region was a determinant of the rate of cervical cancer in American Indian women.
For example, women from Plains tribes have a higher cervical cancer incidence than those from
coastal tribes (Becker, et al., 2008). In this analysis, 90% of American Indian women reported
being covered by health insurance. Health behavior statistics in this analysis regarding American
Indian women have to be interpreted with caution. The Indian Health Service reports data only
for women who are members of federally recognized tribes (Becker, et al., 2008). It was not
possible to determine if respondents in this analysis were members of federally recognized tribes.
Black/non-Hispanic women and Asian women had the lowest HPV vaccination rates,
44% and 40%, respectively. Black and Asian women had a lower likelihood of receiving the
HPV vaccine when compared to white women in the regression analysis (OR=.744, 95%
CI=0.692-0.801 and OR=0.795, 95% CI=0.746-0.847 respectively). Gynecological exam rates
for these groups were 53% and 28% which is lower than those reported by the CDC in 2008
(80% and 65.6%, respect for all women). The health insurance coverage rate was 91% for Black
and 94% for Asian women in this analysis.
It was demonstrated by Kessels et al (2012), that black women were less likely to receive
the HPV vaccine. Licht et al (2010) determined that Black and Asian women were less likely to
receive the HPV vaccine when compared to white women. Race was shown by Bendik et al
(2011) to be a barrier to HPV vaccination. Disregarding the Biracial/Multiracial category, all the
minority races in this analysis, when compared to White/non-Hispanic women, had a lower
percentage of HPV vaccination and demonstrated in the logistic regression model, a lower
likelihood to receive the HPV vaccine.
Several studies have found that lower cervical cancer screening rates are associated with
minority status and lower socioeconomic status. In addition, lower socioeconomic status has also
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been associated with lacking health insurance (Kahn, et al., 2008, Rodriques, et al., 2005,
Solomon, et al., 2007, Swan, et al., 2003). In this analysis, having health insurance, most notably
being covered by parental insurance versus having no insurance coverage (OR=1.845, 95%
CI=1.689-2.016), increased the likelihood of receiving the HPV vaccine. Insurance coverage has
also been linked to increased gynecological exam rates (CDC, 2009). It was not possible to
establish the students’ or parents’ socioeconomic status, which is a limitation of the current
study.
Educational status has also been shown to influence cervical cancer screening rates (CDC
Surveillance of Health Status in Minority Communities, 2009). In 2009, the CDC reported that
approximately 83% of women with some college education received a Pap smear while only
70% of women with only a high school diploma were screened for cervical cancer. Among
women with no high school diploma, the screening rate was only 61%. In this analysis, 55% of
women received a gynecological exam, which is lower than the CDC reported rate for women
with some college education. It should be noted that in this study, gynecologic examination does
not imply that a Pap smear was done. Again, the Pap smear rate reported by the CDC includes
all women with some college education, not just those 18-26 years of age, which is a limitation
of this study in that only college women are included in the analysis.
Women who lack access to Pap testing or are less likely to receive the Pap test may
realize the greatest benefit from receiving the HPV vaccine (Brewer, et al., 2007, Harper, et al.,
2004, Kahn, et al., 2008). In this analysis, Black/non-Hispanic and Asian/Pacific Island women
had the lowest gynecological exam rate (44% and 28%, respectively), despite having high
insurance coverage rates (91% and 94%, respectively). Since Black and Asian women had low
gynecological exam rates they may gain additional benefit from receiving the HPV vaccine.
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Hispanic/Latino women could also realize an increased benefit from HPV vaccination. In the
present study, 46% of Hispanic women received the HPV vaccine and only 44% received a
gynecological exam in the past 12 months. Hispanic/Latino women in this analysis had the
lowest percentage of health insurance coverage (87%). While the HPV vaccine does not negate
the need for future gynecological exams, vaccination may offer some protection to women who
forgo gynecological exams. Changing Pap smear recommendations may also impact the rate at
which college women seek gynecological exams. The new recommendation for average risk
women is not to begin Pap testing until the age of 21, or 3 years after engaging in sexual
intercourse, compared to the previous recommendation that women begin Pap testing at the onset
of sexual intercourse or at 18 years of age (American Cancer Society, 2012). This may impact
future data on gynecological exam rates. It will take at least five years to obtain data based on the
new recommendations. Data on cervical cancer rates even after HPV vaccination will not be
available for decades. It has yet to be determined if the HPV vaccine will maintain its full
effectiveness over an extended amount of time or if a booster vaccine will be necessary (Chang,
et al., 2009, Goldie, et al., 2003).
Creating HPV vaccination programs that concentrate on single racial/cultural groups
could help lessen disparities in rates (Kessels, et al., 2012). Evaluation of community needs is
not limited to racial categories; socioeconomic factors, cultural beliefs, and past relationships
with health care providers all play a role in increasing the levels of preventive care. Increasing
HPV vaccination in college age women could further decrease cervical cancer rates in the United
States (Harper, et al., 2004). It should be recognized that socio-demographics of college women
play a role in decisions they make regarding preventive care. There is a need to focus research on
low income women, lack of insurance and access to health care be an indicator for increased
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health disparities. Studies have shown lower socio-economic status was found to be a predictor
of not receiving the HPV vaccine (Brewer and Fazekas, et al., 2007, Fazekas, et al., 2008, Kahn,
et al., 2007).
The importance of provider recommendation
Provider recommendation has also been shown to increase the likelihood of HPV
vaccination (Brewer, et al., 2007, Colgrove, 2006, Herzog, et al., 2008, Keating, et al., 2008,
Kessels, et al., 2012, Marchand, et al., 2012, Rosenthal, et al., 2011). HPV vaccine acceptance
increases in young women when their health care providers recommend it (Keating, et al., 2008,
Zimet, 2006). When women are not in contact with health care providers, important information
regarding the HPV vaccination and the protection it affords is not given. The systemic review on
HPV vaccine acceptability prepared by Brewer and Frazekas (2007) demonstrated that lack of
physician recommendation is a barrier to vaccination. Marchand et al (2012) reported that 100%
of the women who received the HPV vaccine had done so due to a health care provider
recommendation; the sample (N=178) in this study was mostly Hispanic women.
In this analysis it was found that there was statistical significance (p=.000) in HPV
vaccination rates between women who received a gynecological exam in the past 12 months and
those who did not. A higher percentage of women received the HPV vaccination (55%) when
they had a gynecological exam in the past 12 months, and 43% of women received the vaccine
when they did not have a gynecological exam in the past 12 months. The binary regression
demonstrated that the likelihood of receiving the HPV vaccine increased nearly two fold when a
woman received a gynecological exam (OR=1.936, 95% CI=1.868-2.007).
Physicians also are an educational source for the importance of vaccination. Expanded
research on physician recommendation is warranted. Keating et al (2008) demonstrated that
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physicians face barriers in the recommendation of the HPV vaccine. Physicians found low
reimbursement rates were a barrier to recommendation in a low income geographic region
(Keating, et al., 2008). Investigation focusing on physician HPV vaccine recommendations in
student health centers could provide insight into barriers faced in recommendations to college
women. Increased research regarding provider-patient educational strategies is also warranted.
Strong endorsement from the medical community is needed in the promotion of vaccination.
Endorsement of the HPV vaccine by providers is linked to acceptance of the vaccine by medical
professional organizations (Raley, et al., 2004, Slomovitz and Bodurka, 2007). Limited access to
medical care is a barrier to HPV vaccination (Brewer, et al., 2007, Kessels, et al., 2012). It is
important to realize that provider patient relationships are complex and non-standardized HPV
vaccine recommendation in college age women makes it difficult to predict if recommendations
occur. Physicians reported that discussing STDs with parents may be uncomfortable, thus
missing the opportunity to provide the vaccine before they reach adulthood (Kating, et al., 2008,
Kessels, et al., 2012). Physician discomfort with the topic of STD’s may also be present when
caring for young women.
Past vaccination status and HPV vaccination
Exploring past vaccination demonstrated in the binary regression analysis that if women
received the Hepatitis B vaccine and the influenza vaccine the likelihood that they would receive
the HPV vaccine increased (OR=4.1, 95% CI=3.796-4.428 and OR=2.553, 95% CI=2.465-2.643
respectively). Hepatitis B vaccination series is often required for college matriculation; it was not
surprising that 92% of women received the series in this analysis. The study found that 52% of
women who received the Hepatitis B vaccine received the HPV vaccine. Conversely, when
women did not receive the Hepatitis B vaccine, only 17% of them received the HPV vaccine.
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Influenza vaccination rates were much smaller than Hepatitis B vaccination rates. Only 37% of
respondents received the influenza vaccine. Only 24% of women in the study received both the
influenza and HPV vaccine. What is interesting is that 64% of women that received the
influenza vaccine also received the HPV vaccine. Engaging in preventive health behaviors
(gynecological exams, previous vaccination, and having a source of health insurance) increases
the likelihood of receiving the HPV vaccine.
Age and number of sexual partners and the effect on HPV vaccination
The binary regression demonstrated that age was statistically significant (p=.000); as age
increased, the likelihood of having the HPV vaccination decreased. This may be due to the fact
that the vaccine was approved in 2006, therefore women between the ages of 19-26 were not
exposed to the recommendation to receive the vaccine as 12-year-olds. In 2011, 28% of 13-17
year old girls received all three doses of the vaccine (CDC, 2012). Even if women in the study
were exposed to the vaccination recommendation there is a possibility that they did not receive
it. In this analysis, 61% of the respondents did not receive the vaccine, which indicates that
progress can be made to increase the HPV vaccine rate among the “catch-up” group.
An increase in the number of sexual partners also proved to be statistically significant in
the increase of HPV vaccination (p=.000) in the binary regression analysis. Caskey et al (2009)
showed that a lack of first sexual contact was a barrier to HPV vaccination. Several studies
demonstrated that as the number of sexual partners increased the likelihood of receiving the HPV
vaccine (Bendik, et al., 2011, Caskey, et al., 2009, Jones, et al., 2008). The HPV vaccine offers
the greatest protection against cervical cancer when given before sexual contact. There may be a
misconception among college women that once they engage in sex they should get the HPV

100

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

vaccine. This potential conviction among young women should be reversed. Promoting the
vaccine before sexual contact should be the goal.
Geographic region and HPV vaccination
There was a statistical significance difference in the HPV vaccination between
geographic regions. The Northeast region of the United States had the highest rate of HPV
vaccination at 55%. The Southern region had a vaccination rate of 49%, and both the Midwest
and Western regions had a vaccination rate of 45%. Women who attended college in the
Northeast were more likely to receive the HPV vaccine when compared to the other geographic
regions. It was curious that the Midwest region had the highest percentage of women who
received a gynecological exam in the past 12 months yet had a lower likelihood of HPV
vaccination when compared to the Northeast (OR=.766, 95% CI=.733-.800). This analysis used
only the four board regions of the US as defined by the US Census Bureau. This is a limitation
of this analysis. It would be more useful to be able to break down geographic region further by
state, and even more so by rural and urban areas. Generalizations of HPV vaccination by region
should be avoided. Comparison with this analysis data and future research with more defined
regions may prove to be fruitful.
Caskey et al., (2009) found no significance between HPV vaccination and geographic
region. Current studies which had small sample sizes that were located in varying regions of the
United States had different findings regarding the acceptance of the HPV vaccine and how many
women have received the vaccine (Allen, 2009, Baer, et al., 2000, Bendik, et al., 2011, Caron, et
al., 2009, D’Urso, et al., 2007, Marchand, et al., 2012). Studies such as “HPV Vaccine
Acceptability in a Rural Southern Area” (2008) were able to look at a specific rural community
and gain information pertinent to that explicit community. Continuation of research that isolates
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individual communities and then compares that community to a specific region could further add
understanding to HPV vaccination barriers.
Receiving STD information and HPV vaccination
Education emphasizing the risk of HPV virus and the benefits gained from HPV
vaccination could further decrease cervical cancer rates in the United States. In this analysis,
receiving information regarding STD’s from the student’s university was statistically significant
(p=.005) in the binary regression analysis. The likelihood of receiving the HPV vaccine
increased when students received STD information (OR=1.05, 95% CI=1.01-1.086). There was
also statistical significance (p=.000) difference between the women who received and those who
did not receive STD information. This was expected with such a large sample size (N=68,193).
55% of respondents received STD information from their college/university. Black women had
the highest rate of receiving STD information, at 65%, and American Indian/Alaskan
Native/Native American women demonstrated the lowest percentage of 50.
There was no way to determine the content of the STD information gathered by the
respondents or even if the information contained any educational material regarding HPV. This
is a limitation of the study. It would be most useful to be able to evaluate educational
information and HPV vaccination rates. There are public service announcements regarding the
benefits of the HPV vaccine; what is not known is the frequency or viewership of these
television announcements. There are also a number of un-vetted social media informational
websites that either promote or denounce HPV vaccination (Ache, et al., 2008).

Increased

study of informational programming concerning HPV vaccination would be useful. Kelly, et al
(2009) found that the information provided by mass media fails to emphasis that HPV is often a
symptomless virus until the formation of cervical cancer and that condoms do not guarantee
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100% protection from the virus. Study authors point to the need for tailored educational methods
regarding HPV (Avis, et al., 2003, D’Urso, et al., 2007, Kahn, et al., 2007, Parson, et al, 2000,
Yacobi, et al., 1999). In a 2007 study conducted at a historically black college 64% of students
had never heard of the HPV virus (D’Urso, et al., 2007). This was not the case in a large state
university in New Hampshire. Approximately 85% of students had heard of the Gardasil®
vaccine (Caron, et al., 2009). Greater knowledge of the HPV virus is linked with an increased
intent to receive the vaccine (Jones, et al., 2008). Lack of knowledge concerning the HPV virus
and its related diseases is a barrier to vaccination (Blumenthal, et al., 2008, Brewer, et al, 2007,
Rosenthal, et al., 2011). Specific educational interventions regarding the benefits of the HPV
vaccine could be practical in decreasing cervical cancer disparities between minority groups.
Increased research exploring HPV virus education in college age women is necessary.
This study was limited to exploring the barriers, demographics and health behaviors
related to HPV vaccination rates. The pseudo-R2=.156 did not provide a large explanatory value
in the binary regression model. This analysis could not evaluate the entirety of the Health Belief
Model’s constructs. It would be desirable to explore the barriers to HPV vaccine along with
perceived susceptibility, perceived severity, perceived benefits, and cues to action, arguably all
of which contribute to an individual’s motivation to receive the HPV vaccine (Brewer, et al.,
2007, Nadarzynski, et al., 2012, McAlearney, et al., 2010). Maintaining a large sample size of
college age women and exploring all the Health Belief Model’s constructs would be of use,
although it may be unrealistic.
Strengths of the analysis
The strength of this research is its large sample size. Research with a sample size over
1,500 which explores HPV vaccination rates and barriers to vaccination was not readily
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available. Information gathering behavior is another dimension; “did you receive information
regarding STD’s” that universities use to gauge their educational efforts was unprompted.
Furthermore, data regarding rates of gynecological exams in college women is useful comparing
HPV vaccination among diverse groups of women since Pap smears which screen for cervical
cancer and the HPV vaccine which aims to reduce the incidence. Comparison to Hepatitis B and
influenza vaccine was novel.
Limitations of the analysis
A limitation of secondary data analysis is that results cannot be generalized to all college
age women. This is due to the fact that institutions that participate in the National College
Health Assessment are self-selected. Secondary analysis is limited to the data set available. With
the dependent variable “Have you received the HPV vaccine?” one has to assume at least one
dose of the vaccine. There are no questions included in the survey that asks respondents how
many doses of the series they received or if they completed the series. Another limitation is that
independent variable, “Have you received information on the following topic from your college
or university, sexually transmitted disease/infection?” is not specific to HPV and there is no way
to evaluate the information received. Geographic regions are also defined in four board regions
which does not take into account the difference between vaccination rates in rural and urban
areas. While general barriers -- for example, lack of insurance and/or lack of gynecological
exams -- can be indicated, it is impossible to know the circumstances that affected the variables.
The entire survey relies on self-reporting which is a limitation of survey analysis.
Self-reporting dealing with sensitive issues, such as the number of sexual partners, may
cause respondents to answer in a socially acceptable way instead of being honest. There is no
way to gauge the veracity of the answers reported by the respondents. Surveys such as this one
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also rely on the introspective ability of the respondents. Questions dealing with time frames,
such as “Have you had a gynecological exam in the past 12 months,” may lead the respondents
to answer the question incorrectly because they inaccurately remember. There is even the danger
that respondents answer inaccurately intentionally. Response bias, the tendency to answer a
certain way, can cause inaccurate responses. Behavioral researchers nonetheless must heavily
rely on self-reporting, even knowing that there are multiple limitations in doing so.
Conclusion
In this secondary data analysis race, age, number of sexual partners, lacking a
gynecological exam in the past 12 months, not receiving the Hepatitis B and influenza vaccine,
and not having a source of health insurance, were shown to be possible barriers to HPV
vaccination in college women. HPV vaccination in this analysis was influenced by geographic
location, but this should be viewed with caution since it could not determine which state the
respondents were from. It would have been even more useful if geographic location could be
broken down by rural or urban location. Receiving STD information from one’s college was
statistically significant in the binary regression model (p< 001). There is no way to determine the
content of the STD information received by the respondents. The model had a low explanatory
value, as determined by the pseudo-R2=.156. This is most likely due to the fact that among the
limited number of barriers that were explored, perceived risk, perceived susceptibility, perceived
severity, and cues to action could not be determined. This analysis does provide a large sample
that gives greater insight into HPV vaccination rates among racial categories and the influence of
health behaviors.
Increasing the acceptance of preventive health behaviors in college age women may serve
as an impetus to increase HPV vaccination rates. Racially sensitive health promoting activities
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could benefit colleges that wish to decrease health disparities in their student population.
Keeping a wide focus of women’s health, such as promoting gynecological exams, not only
affords women the opportunity to receive a HPV vaccine recommendation but also other
preventive health care such as Pap smears and other missed vaccinations. Increasing the
knowledge of the HPV virus and vaccine may prove essential to increasing vaccination rates in
college age women.
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Chapter 6
Conclusion
Introduction
In this study of college women, White/non-Hispanic women had a higher HPV
vaccination rate than the minority women. Binary logistic regression demonstrated minority
women had a lower likelihood of receiving the HPV vaccine. Health behaviors, such as
receiving a gynecological exam in the past 12 months and receiving the Hepatitis B and
influenza vaccines, increased the likelihood of receiving the HPV vaccine. Among the racial
categories, White/non-Hispanic women had the highest percentage of receiving a gynecological
exam within the past 12 months, receiving the Hepatitis B vaccine, and having a source of health
insurance. Promoting preventive health behaviors, such as receiving a regular gynecologic exam
and maintaining preventive vaccines, could provide an opportunity to educate women on the
benefits of HPV vaccination. The Affordable Care Act (2010) calls for increased health
insurance coverage and specifically targets an increase in preventive care. The legislation also
targets decreasing health disparities in minority populations. Patient-centered medical homes are
considered to be an avenue for increasing the amount of preventive care offered. Incentives are
offered for the increased use of electronic medical records (EMRs) by health providers.
Currently the medical home model is being explored, and EMRs are seeing increased
implementation. Future research will surely focus on medical outcomes if there is widespread
implementation of medical homes and EMRs (Patient Centered Homes, Health Affairs, 2010). It
would be of interest to follow HPV vaccination rates of the “catch-up” group after the new
legislation is fully realized. State-by-state evaluations may be necessary due to the fact the
individual states may enact new legislation in unique ways. Currently EMRs are not contained in
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a centralized data base, which means the portability of medical records is not fully available,
potentially problematic if patients seek treatment in different hospitals or even states (Patient
Centered Homes, Health Affairs, 2010).
Unlike the United Kingdom and Australia, there is not a centralized adult vaccine registry
in the U.S. Tracking adult vaccination rates can prove difficult. People in the United States
often seek care in multiple health care venues (i.e., a college student may have a vaccine record
with a primary care physician in their home town, and a vaccine record in the student health
department at their university). The evolution of the EMR may see the formation of a
comprehensive medical record, but that is yet to come to fruition.
Policy Implications
Future preventive measures that may be proposed due to the Affordable Care Act (2010)
includes increasing adult vaccination rates. The goal of expanding preventive health measures is
to reduce health disparities, such as cervical cancer. Preventive health care expansion may
advocate the HPV vaccine in women age 26 and younger. The President’s Cancer Panel (2012)
created an HPV vaccine advisory board and has indicated that increasing HPV vaccination rates
is a priority. However, the committee is currently focused on adolescent girls aged 11-12. If
centralized and coordinated care of the medical home model comes to fruition, preventive
services for adult HPV vaccination may be a focus. The Affordable Care Act (2010) also calls
for mandated health insurance coverage. As of September 23, 2010, this act mandated that the
Department of Health and Human Services require that new health plans include coverage for the
HPV vaccine. Presently it is unclear whether all socioeconomic groups will benefit from this
new legislation. Hypothetically, increased insurance coverage could increase HPV vaccine rates
in women that previously did not have health insurance. Increased use of electronic medical
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record along with coordinated preventive care could provide physicians with the information and
the opportunity they need to suggest vaccination, i.e., “I see that you did not receive the HPV
vaccine, here are the benefits and risks.” Physician recommendation in the “catch-up” group is a
vital component of the effort to increase HPV vaccination rates. Additionally, the development
of a Community Preventive Services Task Force, also included in the Affordable Care Act
(2010), has the primary goal to increase preventive health services. One focus of the task force
is to expand care for women.
Conclusion
In this analysis black, Hispanic, and Asian college women ages 18-26 all demonstrated
lower HPV vaccination rates when compared to white women. Tailoring health promotion
activities to specific racial populations may help lessen disparities in HPV vaccination rates.
Student health departments could tailor promotion activities to their specific student populations.
Advocacy of increased provider visits (i.e., gynecological exams) and other preventive health
services (such as influenza vaccine drives) in the female student population could be a window
of opportunity for increased HPV education and vaccination. Acknowledgment that minorities
have lower HPV vaccination rates and gynecological exam rates allows for the recognition that
specialized health promotion activities may be an avenue for designing educational strategies to
lessen disparities. Considering that Healthy People 2020 calls for a HPV vaccination rate of
80% in women, policy makers and the medical community may decide that strategies to increase
the vaccination rate in women 18-26 years of age is warranted. This research aimed to provide
an understanding of HPV vaccination rate disparities and potential barriers, which is important
when formulating strategies to increase vaccination rates.

109

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

References
Ache, K., Wallace, L. (2008). Human papillomavirus vaccination coverage on YouTube.
American Journal of Preventive Medicine, 35(4), 389-392.

Adams, M., Jasani, B., Fiander, A. (2009). Prophylactic HPV vaccination for women over 18
years of age. Vaccine, 27(25), 3391-3394.

Allen, J., Mohllajee, A., Shelton, R., Othus, M., Fontenot, H., Hanna, R. (2009). Stage of
adoption of the human papillomavirus vaccine among college women. Preventive Medicine,
48(5), 420-425.

American College Health Association. (2012, January 13). Who are we? Retrieved from
http://www.acha.org/About_ACHA/Who_We_Are.cfm

American College Health Association-National College Health Assessment. (2012, January 13).
Generalizability, reliability, and validity analysis. Retrieved January 13 from
http://www.acha-ncha.org/grvanalysis.html

American College Health Association-National College Health Assessment. (2012, January 13).
The premier student health survey. Retrieved from http://www.achancha.org/

American Public Health Association, Frincu-MKallos, C., (2009, December 16). Less Than Half
of College Women Vaccinated Against HPV. Retrieved from
http://www.medscape.com/viewarticle/712516

American Public Health Association. (2010, December 16). Adult Vaccine Coverage. Retrieved
from http://www.apha.org/advocacy/
110

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Avis, M., Johnson, S., Philips, Z., & Whynes, D. K. (2003). Human papillomavirus and the value
of screening: Young women's knowledge of cervical cancer. Health Education Research,
18(3), 318-328.

Baer, H., Allen, S., & Braun, L. (2000). Knowledge of human papillomavirus infection among
young adult men and women: Implications for health education and research. Journal of
Community Health, 25(1), 67.

Balong, J., (2009). The Moral Justification for a Compulsory Human Papillomavirus Vaccination
Program. American Journal of Public Health, 99(4), 616.

Becker, M. (1974). The health belief model and personal health behavior. Health Education
Monographs, 2:324-508.

Bendik, M., Mayo, R., Parker, V. (2011). Knowledge, perceptions, and motivations related to
HPV vaccination among college women. Journal of Cancer Education: The Official Journal
of the American Association for Cancer Education, 26(3), 459.

Blumenthal, J., Heyman, K., Trocola, R., Slomovitz, B. (2008). Barriers to acceptance of the
human papillomavirus prophylactic vaccine. Journal of Pediatric Infectious Diseases, 3(3),
159-165.

Brandt, H., McCree, D., Lindley, L., Sharpe, P., Hutto, B., Brandt, H. (2005). An evaluation of
printed HPV educational materials. Cancer Control: Journal of the Moffitt Cancer Center,
12 Supplemental 2, 103.

111

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Brewer, N. & Fazekas, K. (2007). Predictors of HPV vaccine acceptability: A theory-informed,
systematic review. Preventive Medicine, 45, 107-114.

Burak, L., Meyer, M. (1997). Using the health belief model to examine and predict college
women's cervical cancer screening beliefs and behavior. Health Care for Women
International, 18(3), 251.

Campos, N., Kim, J., Castle, P., Ortendahl, J., O'Shea, M., Diaz, M. (2012). Health and
economic impact of HPV 16/18 vaccination and cervical cancer screening in eastern Africa.
International Journal of Cancer.Journal International Du Cancer, 130(11), 2672.

Caron, R., Kispert, E., McGrath, R. (2009). Human papillomavirus (HPV) vaccine: Attitudes,
behaviors, and beliefs of at-risk women. The Internet Journal of Health, 9(2), July, 5, 2012.

Caskey, R., Lindau, S., Alexander, G., Caskey, R., Lindau, S., Alexander, G. (2009). Knowledge
and early adoption of the HPV vaccine among girls and young women: Results of a national
survey. Journal of Adolescent Health, 45(5), 453-462.

Castellsagué, X., Muñoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K. (2011). Endof-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18)
recombinant vaccine in adult women 24–45 years of age. British Journal of Cancer, 105(1),
28-37.

112

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Cates, J., Brewer, N., Fazekas, K., Mitchell, C., Smith, J., Cates, J. (2009). Racial differences in
HPV knowledge, HPV vaccine acceptability, and related beliefs among rural, southern
women. The Journal of Rural Health: Official Journal of the American Rural Health
Association and the National Rural Health Care Association, 25(1), 93.

Centers for Disease Control and Prevention. (2009, November 22). Surveillance of Health Status
in Minority Communities. Retrieved from
http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6006a1.htm

Center for Disease Control Cancer Fact Sheet. (2010, January 4). Human Papillomavirus.
Retrieved from http://www.cdc.gov/std/hpv/stdfact-hpv.htm

Center for Disease Control Cancer Fact Sheet. (2012, January 3). Sexually Transmitted Diseases
Treatment Guidelines. Retrieved from http://www.cdc.gov/std/treatment/2010/default.htm

Centers for Disease Control and Prevention. (2011, November 22). Morbidity and Mortality
Weekly Report. Retrieved from http://www.cdc.gov/mmwr/preview/ind2011_su.html

Centers for Disease Control and Prevention. (2012, November 22). Cervical Screening
Guidelines for Average Risk Women. Retrieved from
http://www.cdc.gov/cancer/cervical/pdf/guidelines.pdf
Cermak, M., Cottrell, R., Murnan, J., Cermak, M., Cottrell, R., Murnan, J. (2010). Women’s
knowledge of HPV and their perceptions of physician educational efforts regarding HPV
and cervical cancer. Journal of Community Health, 35(3), 229-234.

113

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Chang, Y., Brewer, N., Rinas, A., Schmitt, K., Smith, J. (2009). Evaluating the impact of human
papillomavirus vaccines. Vaccine, 27(32), 4355-4362.
Charo, R. (2007). Politics, parents, and prophylaxis — mandating HPV vaccination in the United
States. New England Journal of Medicine, 356(19), 1905-1908.

Colgrove, J. (2006). The ethics and politics of compulsory HPV vaccination. Vaccine, 24(22),
4812.

Daley, E., Hernandez, N., Buhi, E., Romero-Daza, N., Young, L., Kolar, S. (2012). American
public health association: Human papillomavirus vaccination status in an ethnically and
racially diverse group of females US college students: Unvaccinated, initiated, and
completed. Prevention and Wellness across the Life Span, APHA 140th Annual Meeting and
Expo: October 29, 2012, San Francisco, CA.

Dempsey, A., Gebremariam, A., Koutsky, L., Manhart, L. (2008). Using risk factors to predict
human papillomavirus infection: Implications for targeted vaccination strategies in young
adult women. Vaccine, 26(8), 1111-1117.

Dunne, E., Unger, E., Sternberg, M., McQuillan, G., Swan, D., Patel, S. (2007). Prevalence of
HPV infection among females in the United States. JAMA: The Journal of the American
Medical Association, 297(8), 813.

D'Urso, J., Thompson-Robinson, M., Chandler, S. (2007). HPV knowledge and behaviors of
black college students at a historically black university. Journal of American College
Health, 56(2), 159-163.

114

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Elbasha, E., Galvani, A., Elbasha, E., Galvani, A. (2005). Vaccination against multiple HPV
types. Mathematical Biosciences, 197(1), 88.

Fazekas, K., Brewer, N., Smith, J. (2008). HPV vaccine acceptability in a rural southern area.
Journal of Women's Health, 17(4), 539-548.

Fernández, M., Allen, J., Mistry, R., Kahn, J., Fernández, M., Allen, J. (2010). Integrating
clinical, community, and policy perspectives on human papillomavirus vaccination. Annual
Review of Public Health, 31, 235.

Garland, S., Brotherton, J., Skinner, S., Pitts, M., Saville, M., Mola, G. (2008). Human
papillomavirus and cervical cancer in Australasia and Oceania: Risk-factors, epidemiology
and prevention. Vaccine, 26, M80-M88.

Garland, S., Hernandez-Avila, M., Wheeler, C., Perez, G., Harper, D., Leodolter, S. (2007).
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New
England Journal of Medicine, 356(19), 1928-1943.

Gerend, M., Magloire, Z. (2008). Awareness, knowledge, and beliefs about human
papillomavirus in a racially diverse sample of young adults. Journal of Adolescent Health,
42(3), 237-242.

Gertig, D., Brotherton, J., Saville, M. (2011). Measuring human papillomavirus (HPV)
vaccination coverage and the role of the national HPV vaccination program register,
Australia. Sexual Health, 8, 171-178.

115

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Giambi, C., Donati, S., Declich, S., Salmaso, S., Degli, A., Marta, L., Alibrandi, M. (2011).
Estimated acceptance of HPV vaccination among Italian women aged 18–26 years. Vaccine,
29(46), 8373-8380.

Giede, C., McFadden, L., Komonoski, P., Agrawal, A. (2010). Acceptability of HPV vaccination
among women attending the university of saskatchewan student health services. Journal of
OB/GYN Canada, 32(7):679-86.

Goldie, S., Grima, D., Kohli, M., Wright, T., Weinstein, M., Franco, E. (2003). A comprehensive
natural history model of HPV infection and cervical cancer to estimate the clinical impact of
a prophylactic HPV-16/18 vaccine. International Journal of Cancer.Journal International
Du Cancer, 106(6), 896.

Goldie, S., Daniels, N., Goldie, S., Daniels, N. (2011). Model-based analyses to compare health
and economic outcomes of cancer control: Inclusion of disparities. Journal of the National
Cancer Institute, 103(18), 1373-1386.

Hall, B., Howard, K., McCaffery, K. (2008). Do cervical cancer screening patient information
leaflets meet the HPV information needs of women? Patient Education and Counseling,
72(1), 78-87.

Harper, D., Franco, E., Wheeler, C., Ferris, D., Jenkins, D., Schuind, A. (2004). Efficacy of a
bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus
types 16 and 18 in young women: A randomized controlled trial. The Lancet, 364(9447),
1757-1765.

116

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Hernandez, N. (Conference November 17, 2009). Less than half of college women vaccinated
against HPV; American Public Health association 137th annual meeting; Medscape.
Philadelphia, PA.

Herzog, T., Huh, W., Downs, L., Smith, J., Monk, B., Herzog, T. (2008). Initial lessons learned
in HPV vaccination. Gynecologic Oncology, 109(2), S4-S11.

Jones, M., Cook, R., Jones, M., & Cook, R. (2008). Intent to receive an HPV vaccine among
university men and women and implications for vaccine administration. Journal of
American College Health, 57(1), 23-32.

Kahn J., Rosenthal S., Hamann, T., Bernstein D. (2003). Attitudes about human papillomavirus
vaccine in young women. International Journal of STD AIDS, 14(5), 300.

Kahn, J., Rosenthal, S., Yan, J., Bin, H., Namakydoust, A., Zimet, G. (2008). Rates of human
papillomavirus vaccination, attitudes about vaccination, and human papillomavirus
prevalence in young women. Obstetrics and Gynecology, 111(5), 1103.

Kahn, J., Zimet, G., Bernstein, D., Riedesel, J., Lan, D., Huang, B. (2005). Pediatricians’
intention to administer human papillomavirus vaccine: The role of practice characteristics,
knowledge, and attitudes. Journal of Adolescent Health, 37(6), 502-510.

Kahn, J, Rosenthal, S., Jin, Y., Huang, B., Namakydoust, A., Zimet, G. (2008). Rates of human
papillomavirus vaccination, attitudes about vaccination, and human papillomavirus
prevalence in young women. Obstetrics and Gynecology, 111(5), 1103.

117

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Kahn, J., Slap, G., Bernstein, D., Tissot, A., Kollar, L., Hillard, P. (2007). Personal meaning of
human papillomavirus and Pap test results in adolescent and young adult women. Health
Psychology, 26(2), 192-200.

Keane, M., Walter, M., Patel, B., Moorthy, S., Stevens, R., Bradley, K. (2005). Confidence in
vaccination: A parent model. Vaccine, 23(19), 2486-2493.

Keating, K., Brewer, N., Gottlieb, S., Liddon, N., Ludema, C., Smith, J. (2008). Potential barriers
to HPV vaccine provision among medical practices in an area with high rates of cervical
cancer. Journal of Adolescent Health, 43(4), S61-S67.

Kelly, B., Leader, A., Mittermaier, D., Hornik, R., Cappella, J. (2009). Health communication in
mass media: The HPV vaccine and the media: How has the topic been covered and what are
the effects on knowledge about the virus and cervical cancer? Patient Education and
Counseling, 77(2), 308-313.

Kessels, S., Marshall, H., Watson, M., Braunack-Mayer, A., Reuzel, R., Tooher, R. (2012).
Factors associated with HPV vaccine uptake in teenage girls: A systematic review. Vaccine,
30(24), 3546-3556.

Kim, J. (2008). Health and economic implications of HPV vaccination in the United States. New
England Journal of Medicine, the, 359(8), 821.
Kobetz, E., Kornfeld, J., Vanderpool, R., Finney-Rutten, L., Parekh, N., O’Bryan, G. (2010).
Knowledge of HPV among United States Hispanic women: Opportunities and challenges
for cancer prevention. Journal of Health Communication, 15 Supplement 3, 22.

118

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Lambert, E. (2001). College students' knowledge of human papillomavirus and effectiveness of a
brief education intervention. Journal American Board of Family Practice, 14(3), 178-183.

Lenselink, C., Schmeink, C., Melchers, W., Massuger, L., Hendriks, J., van Hamont, D. (2008).
Young adults and acceptance of the human papillomavirus vaccine. Public Health, 122(12),
1295-1301.

Leval, A., Sundström, K., Ploner, A., Arnheim Dahlström, L., Widmark, C., Sparén, P. (2011).
Assessing perceived risk and STI prevention behavior: A national population-based study
with special reference to HPV. Plos One, 6(6)

Licht, A., Murphy, J., Hyland, A., Fix, B., Hawk, L., Mahoney, M. (2010). Is use of the human
papillomavirus vaccine among female college students related to human papillomavirus
knowledge and risk perception? Sexually Transmitted Infections, 86(1), 74.

Liebler, C., Halpern-Manners, A. (2008). A practical approach to using multiple-race response
data: a bridging method for public-use microdata. Demography, 45(1), 143-155.

Marchand, E., Glenn, B., Bastani, R., Marchand, E., Glenn, B., Bastani, A., et al. (2012). Low
HPV vaccine coverage among female community college students. Journal of Community
Health, 37(6), 1136-1144.

Markowitz, L. E. (2007). HPV vaccines prophylactic, not therapeutic. The Journal of the
American Medical Association, 298(7), 805.

119

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Markowitz, L., Dunne, E., Saraiya, M., Lawson, H., Chesson, H., Unger, E., (2007).
Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee
on Immunization Practices, Centers for Disease Control and Prevention. (March 23)

Marlow, L., Forster, S., Wardle, J., Waller, J. (2009). Mothers' and adolescents' beliefs about risk
compensation following HPV vaccination. Journal of Adolescent Health, 44(5), 446-451.

Marlow, L., Waller, J., & Wardle, J. (2007). Public awareness that HPV is a risk factor for
cervical cancer. British Journal of Cancer, 97(5), 691-694.

Mays, V., Ponce, N., Washington, D., Cochran (2003). Classification of Race and Ethnicity.
Annual Review of Public Health, 24, 83-110.

McAlearney, A. S., Song, P. H., Rhoda, D. A., Tatum, C., Lemeshow, S., Ruffin, M. (2010).
Ohio Appalachian women's perceptions of the cost of cervical cancer screening. Cancer,
116(20), 4727.

McCaffery, K. J., Irwig, L., Chan, S. F., MacAskill, P., Barratt, A., Lewicka, M. (2008). HPV
testing versus repeat pap testing for the management of a minor abnormal pap smear:
Evaluation of a decision aid to support informed choice. Patient Education and Counseling,
73(3), 473-481.

McPartland, T. S., Weaver, B. A., Lee, S., & Koutsky, L. A. (2005). Men's perceptions and
knowledge of human papillomavirus (HPV) infection and cervical cancer. Journal of
American College Health, 53(5), 225-230.

120

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Nadarzynski, T., Waller, J., Robb, K. A., Marlow, L. A. V., Nadarzynski, T., Waller, J. (2012).
Perceived risk of cervical cancer among pre-screening age women (18-24 years): The
impact of information about cervical cancer risk factors and the causal role of HPV.
Sexually Transmitted Infections, 88(6), 400.

National Cancer Institute (NCI) at the National Institute of Health (NIH). (2012, October 10).
Cervical cancer fact sheet. Retrieved from
http://www.cancer.gov/cancertopics/factsheet/Risk/HPV

National Institute of Health (NIH). (2012, October 10). SEER Data: Cervical Cancer. Retrieved
from http://seer.cancer.gov/statfacts/html/cervix.html

National Institute of Health (NIH). (2012, November 8). Human Papillomavirus. Retrieved from
http://www.nih.gov/news/health/nov2012/nichd-08.htm

National Cancer Institute (NCI). (2009, September 15). Fact Sheet, A snapshot of cervical
cancer. Retrieved from www.cancer.gov/aboutnci/servingpeople/cancer-snapshots

National Center of Educational Statistics. (2012, January 13). Higher education; statistical rates
by gender. Retrieved from http://nces.ed.gov/

National Conference of State Legislatures. (2013, February 23). HPV Vaccine, Retrieved from
http://www.ncsl.org/issues-research/health/hpv-vaccine-state-legislation-and-statutes.aspx

Parsons, J. (2000). Perceptions of the benefits and costs associated with condom use and
unprotected sex among late adolescent college students. Journal of Adolescence, 23(4), 377.

121

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

“Patient-Centered Medical Homes,” Health Affairs, September 14, 2010.

Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §2702, 124 Stat. 119, 318-319
(2010).

Phillips, Z., Johnson, S., Avis, M., Whynes, D. (2003). Human papillomavirus and the value of
screening: Young women's knowledge of cervical cancer. Health Education Research
Theory and Practice, 18(3), 318-328.

Poland, G. (2010). Evaluating existing recommendations for hepatitis A and B vaccination. The
American Journal of Medicine, 118(10), 16-20.

Pruitt, S. (2010). Geographic disparity, area poverty, and human papillomavirus vaccination.
American Journal of Preventive Medicine, 38(5), 525-533.

Caron, R., Kispert, E., McGrath R. (2009). Human papillomavirus (HPV) vaccine: Attitudes,
behaviors, and beliefs of at-risk women. The Internet Journal of Health, 9(2)

Raffle, A. (2007). Challenges of implementing human papillomavirus (HPV) vaccination policy.
BMJ (British Medical Journal), 335(7616), 375-379.

Raley, J., Followwill, K., Zimet, G., Ault, K. (2004). Gynecologists' attitudes regarding human
papilloma virus vaccination: A survey of fellows of the American college of obstetricians
and gynecologists. Infectious Diseases in Obstetrics & Gynecology, 12(3-4), 127.

122

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Ramirez, J., Ramos, M., Clayton, L., Kanowitz, S. (1997). Genital human papillomavirus
infections: Knowledge, perception of risk, and actual risk in a nonclinic population of young
women. Journal of Women's Health / the Official Publication of the Society for the
Advancement of Women's Health Research, 6(1), 113.

Riedesel, J., Rosenthal, S., Zimet, G., Bernstein, D, Huang, B., Lan, D. (2005). Attitudes about
human papillomavirus vaccine among family physicians. Journal of Pediatric and
Adolescent Gynecology, 18(6), 391.

Rosenthal, S. (2008). Uptake of HPV vaccine: Demographics, sexual history and values,
parenting style, and vaccine attitudes. Journal of Adolescent Health, 43(3), 239.

Rosenthal, S., Weiss, T, Zimet, G. (2011). Predictors of HPV vaccine uptake among women
aged 19–26: Importance of a physician's recommendation. Vaccine, 29(5), 890-895.

Schiffman, M., Castle, P., Jeronimo, J., Rodriguez, A., Wacholder, S., Schiffman, M. (2007).
Human papillomavirus and cervical cancer. The Lancet, 370(9590), 890-907.

Simon, S., American Cancer Society. (2012, December 3). New screening guidelines for cervical
cancer. Retrieved from http://www.cancer.org/cancer/news/new-screening-guidelines-forcervical-cancer

Slomovitz, B. & Bodurka, D. (2007). Grand rounds: HPV vaccine; breaking down the barriers.
Although this preventive measure can save lives, ensuring widespread usage presents a
unique challenge for practitioners. Contemporary OB/GYN, July 7, 2007

123

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Solomon, D., Breen, N., McNeel, T. (2007). Cervical cancer screening rates in the united states
and the potential impact of implementation of screening guidelines. CA: A Cancer Journal
for Clinicians, 57(2), 105.

Swan, J., Breen, N., Coates, R. J., Rimer, B. K., Lee, N. C., Swan, J., et al. (2003). Progress in
cancer screening practices in the united states: Results from the 2000 national health
interview survey. Cancer, 97(6), 1528.

Teitler-regev, S., Shahrabani, S., Benzion, U. (2011) Factors affecting intention among students
to be vaccinated against A/H1N1 influenza: A health belief model approach. Advances in
Preventive Medicine, 2011

United States Preventive Services Task Force. (2012, September 2). Screening for cervical
cancer. Retrieved from http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm

Vanslyke, J., Baum, J., Plaza, V., Otero, M., Wheeler, C., Helitzer, D. (2008). HPV and cervical
cancer testing and prevention: Knowledge, beliefs, and attitudes among Hispanic women.
Qualitative Health Research, 18(5), 584-596.

Vizcaino, A., Moreno, V., Bosch, F., Muñoz, N. (2000). International trends in incidence of
cervical cancer: II. Squamous-cell carcinoma. International Journal of Cancer.Journal
International Du Cancer, 86(3), 429.

Walboomers, J. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer
worldwide. The Journal of Pathology, 189(1), 12.

124

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Waller, J., Marlow, L., Wardle, J. (2009). Anticipated shame and worry following an abnormal
pap test result: The impact of information about HPV. Preventive Medicine, 48(5), 415-419.

Walsh, C., Gera, A., Shah, M., Sharma, A., Powell, J., Wilson, S., (2008). Public knowledge and
attitudes towards human papilloma virus (HPV) vaccination. BMC Public Health, 8, 368.

World Health Organization (2010, December 16). Global Cancer Statistics. Retrieved from
http://www.who.int/hpvcentre/statistics/en/

Wolfe, R., Sharp, L., Lipsky, M. (2002). Content and design attributes of antivaccination web
sites. American Medical Association, 287, 3245-3248.

Yacobi, E. (1999). University students' knowledge and awareness of HPV. Preventive Medicine,
28(6), 535.

Zambrana, R., Breen, N., Fox, S., Gutierrez-Mohamed, M. (1999) Use of cancer screening
practices by Hispanic women: Analyses by subgroup. Preventive Medicine, 29(6), 466-477.

Zimet G., Liddon N., Rosenthal SL., Lazcano-Ponce, E., Allen, B. (2006). Chapter 24:
Psychosocial aspects of vaccine acceptability. Vaccine, 24 Supplement 3.

Zimet, G., Weiss, T., Rosenthal, S., Good, M., Vichnin, M. (2010). Reasons for non-vaccination
against HPV and future vaccination intentions among 19-26year-old women. BMC Women's
Health, 10, 27.

Zimmerman, R. (2006). Ethical analysis of HPV vaccine policy options. Vaccine, 24(22), 4

125

Human Papillomavirus: Identifying Vaccination Rates, etc.

Cohen, T.F.

Appendix A
Center for Disease Control and Prevention Cervical Cancer Screening for the Average-Risk
Female
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PRESIDENT’S CANCER PANEL
NATIONAL CANCER PROGRAM
NATIONAL CANCER INSTITUTE
NATIONAL INSTITUTES OF HEALTH
DEPARTMENT OF HEALTH AND HUMAN SERVICES
CHAIRPERSON BARBARA K. RIMER, DR.P.H.
MEMBER OWEN W ITTE, M.D.
EXECUTIVE SECRETARY ABBY B. SANDLER, PH.D.

Achieving Widespread HPV Vaccine Uptake September 13, 2012
The President’s Cancer Panel held the second workshop in its 2012–2013 series, Accelerating
Progress in Cancer Prevention: The HPV Example, on September 13, 2012, in Arlington, Virginia.
During this workshop, entitled Achieving Widespread HPV Vaccine Uptake, invited participants
discussed factors influencing uptake of the human papillomavirus (HPV) vaccine, gaps in knowledge
related to vaccine use, and potential strategies to achieve widespread adoption of the vaccine.
Representatives from government, academic, nonprofit, and private sectors were present, including an
HPV-related cancer survivor, pediatricians, other physicians, a pharmacist, and experts in medical
decision making, epidemiology, health services research, health communications, and social marketing.
The group emphasized the need to generate enthusiasm for the vaccine among providers and the public in
order to increase uptake. Strategies for enhancing communication and increasing access to the vaccine
were discussed.
Participants presented the most recently available data on HPV vaccine uptake in the United
States and the results of research on factors influencing vaccine-related decision making. Although there
is variability in vaccine uptake among geographic regions and racial/ethnic populations, overall
vaccination rates have plateaued among U.S. girls in recent years and adoption remains low among boys.
Higher adoption rates for other adolescent vaccines (i.e., Tdap and meningococcal vaccines) suggest there
is an opportunity to increase HPV vaccination rates. Participants viewed providers as key influencers of
vaccine uptake and discussed the need to educate providers about HPV-associated diseases (particularly
non-cervical cancers) and the effectiveness of the vaccine in preventing these diseases. Important
messages to communicate to providers are that the vaccine prevents cancer and is most beneficial for
younger, rather than older, adolescents. Well-designed decision aids may foster pediatrician confidence
and skill in communicating with parents and patients about the vaccine. Some participants suggested that
campaigns targeting the general public also may be useful for enhancing awareness of and support for the
vaccine. The potential of social marketing for disseminating positive communication messages was
discussed, as was the power of narratives for illustrating the burden of HPV-associated disease and the
effectiveness of the vaccine in preventing suffering associated with these diseases.
Workshop participants also discussed system-level challenges to vaccine adoption. Optimally, the HPV
vaccine would be promoted as part of a broader adolescent health platform that includes other adolescent
vaccines and preventive care. Incentives could be established to encourage physicians to promote HPV
vaccines in this context; however, participants acknowledged that adolescents often do not receive regular
care from pediatricians or family physicians. Making the vaccine available at locations frequented by
adolescents may help improve uptake of the vaccine, including initiation and completion of the series.
School-based programs represent one potential venue for vaccination, although significant policy and
logistical barriers exist in the United States. Another option is to allow other providers, such as dentists
and pharmacists, to administer one or more doses of the vaccine. Robust infrastructure, including
electronic health records and vaccine registries, could help link the components of the so-called medical
neighborhood of vaccine providers and also facilitate reminders and implementation of other evidence129
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based approaches for enhancing vaccine uptake and series completion. Reminders and other system
interventions have been effective in increasing uptake of other vaccines.
Throughout the day, the group discussed challenges of a three-vaccine series and some of the differences
between those who initiate versus complete the series. Recommendations will reflect these differences.
The Panel will summarize findings and recommendations from this meeting, along with the other
meetings in the series, in its 2012–2013 Annual Report to the President of the United States.
6116 Executive Blvd Suite 220 Bethesda, Maryland 20892–8439 Tel: 301-451-9399 Fax: 301-435-1832
E-mail: pcp-r@mail.nih.govWeb site: http://pcp.cancer.gov ♦ ♦ ♦ ♦ ♦
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Appendix C
Brochure
Used by the American College Health Association-National College Health Assessment
for Participant Recruitment
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Definition of Geographic Location
United State Census Bureau Map
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Appendix F
Variable coding, Omnibus Test of Model Coefficients, Model Summary, Hosmer and Lemeshow
Test and Contingency Table, and Classification Table
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The following table (Table A.1) provides the variable coding used in SPSS 20.
Appendix table A.1 Categorical Variables Codings
Frequ

Parameter coding

ency
(1)

(2)

(3)

(4)

(5)

(6)

.000

.000

.000

.000

.000

.000

Black, non Hispanic

3936 1.000

.000

.000

.000

.000

.000

Hispanic or Latino/a

3957

.000 1.000

.000

.000

.000

.000

Asian or Pacific Islander

5852

.000

.000 1.000

.000

.000

.000

763

.000

.000

.000 1.000

.000

.000

39

.000

.000

.000

.000 1.000

.000

844

.000

.000

.000

.000

Northeast

20000

.000

.000

.000

Midwest

13454 1.000

.000

.000

South

19062

.000 1.000

.000

West

13154

.000

50279

White, non Hispanic

Race
American Indian, Alaskan
Native, Native Hawaiian
Biracial or Multiracial
Other

REGION

College/university plan

8334 1.000

.000 1.000
.000

.000

.000 1.000

.000

Primary source of health

Parent's plan

49441

insurance

Another plan

4844

.000

.000 1.000

Do not have health insurance

3051

.000

.000

No

5274

.000

Vaccination/shot: Hepatitis B
Yes

60396 1.000

No

41177

Yes

24493 1.000

No

29670

Yes

36000 1.000

Females last 12 months: Routine

No

29641

gynecological exam

Yes

36029 1.000

.000

Vaccination/shot: Influenza
.000

Received Info: STD/I prevention
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The model is statistically significant (p=.000). Therefore, the null hypotheses
were rejected. Table A.2 demonstrates the Omnibus test provided by SPSS 20.
Table A.2 Omnibus Tests of Model
Coefficients
Chi-square
df
Sig.
Step
11150.346
18
.000
Step 1 Block 11150.346
18
.000
Model 11150.346
18
.000
.

The model summary provided by SPSS 19 provided a large -2 Log likelihood. The
pseudo R-squares were also provided. It was understood that pseudo-R squares should be used
with caution. (See Table A.3)
Table A.3 Model Summary
Step
-2 Log
Cox & Snell Nagelkerke R
likelihood
R Square
Square
a
1
79874.772
.156
.208
a. Estimation terminated at iteration number 4
because parameter estimates changed by less than
.001.
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It was not surprising that the Hosmer and Lemeshow Test did not suggest
goodness of fit. That is common with sample sizes over 13,000. (See Table A.4 and A.5)
Table A.4 Hosmer and Lemeshow Test
Step

Chi-square

1

df

Sig.

18.658

8

.017

Table A.5 Contingency Table for Hosmer and Lemeshow Test
Vaccination/shot: HPV = No
Observed

Step 1

Expected

Vaccination/shot: HPV = Yes
Observed

Total

Expected

1

5633

5703.080

936

865.920

6569

2

4882

4785.431

1661

1757.569

6543

3

4236

4266.368

2386

2355.632

6622

4

3833

3816.546

2738

2754.454

6571

5

3479

3448.710

3076

3106.290

6555

6

3124

3090.567

3409

3442.433

6533

7

2699

2691.984

3826

3833.016

6525

8

2242

2301.260

4326

4266.740

6568

9

1886

1888.077

4687

4684.923

6573

10

1280

1301.979

5331

5309.021

6611

Table A.6 provides the predicted percentage of cases based on the full logistic regression model.
Table A.7 Classification Tablea
Observed

Predicted
Vaccination/shot: HPV
No

Step 1

Vaccination/shot: HPV

Yes

Percentage
Correct

No

22435

10859

67.4

Yes

11196

21180

65.4

Overall Percentage

66.4

a. The cut value is .500
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Executive Summary

Human Papillomavirus: Identifying Vaccination Rates, Barriers, and Information
Gathering among College Women ages 18-26

Background
The Center for Disease Control and Prevention recommends the Human Papillomavirus
(HPV) vaccine for women up to the age of 26. HPV is the most common sexually transmitted
disease (STD) in the United States. The majority of cervical cancers are the result of HPV
infection. Women age 20-24 are at the highest risk for HPV infection. The presence of the virus
is difficult to detect since HPV is often asymptomatic and the development of cancer can take
decades. Increasing the HPV vaccination rate has been of interest to public health authorities.
The current focus is to increase the HPV vaccination rate among adolescent girls 11-12 years old
or before they enter the sixth grade. The vaccine affords women the most benefit if it is
administered prior to first sexual intercourse. HPV is a transient virus and women may still
realize some protective benefit of the vaccine even after engaging in sexual intercourse.
Purpose
The purpose of this analysis was to report HPV vaccination rates and barriers to
vaccination among a racially diverse population of college women between the ages of 18-26. A
large data set was obtained from the American College Health Association’s National College
Assessment (ACHA-NCHA) from the following college semesters, fall 2008, spring and fall
2009, and fall 2010. The large sample size (N=68,193) allowed the researcher to examine
demographic variables (race, age, geographic location) and the effects those variables had on
HPV vaccination rates. Additionally, health behaviors (e.g. gynecological exam, past Hepatitis
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B and influenza vaccination, receiving STD information, and number of sexual partners) were
also analyzed for the influence they had on HPV vaccination rates.
Findings
In this analysis, 49% of all women received the HPV vaccine. It was determined that
White/non-Hispanic women had the highest HPV vaccination rate (51%). American
Indian/Alaskan Native/Native Hawaiian and Hispanic/Latino women had HPV vaccination rates
of 47% and 46%, respectively. Black/non-Hispanic and Asian/Pacific Islander women had the
lowest HPV vaccination rates (44% and 40%, respectively). Further analysis demonstrated that
minority women in this data set had a lower likelihood of receiving the HPV vaccine when
compare to White/non-Hispanic women. White/non-Hispanic women also had the highest rate
of receiving a gynecological exam in the past 12 months when compared to minority women.
Age was also predictive of HPV vaccine status. As age increased, the likelihood of receiving the
HPV vaccine decreased.
Women who engaged in the following health behaviors were more likely to receive the
HPV vaccine; received a gynecological exam in the past 12 months, received the Hepatitis B and
influenza vaccine, and had a source of health insurance. Women who received a gynecological
exam in the past 12 months were almost twice as likely to receive the HPV vaccine as those who
did not. Respondents who were covered by their parents’ insurance were also twice as likely to
receive the vaccine. There was a slight increase in the likelihood that women received the HPV
vaccine when they received STD information. An increase in the number of sexual partners was
also shown to increase the likelihood of receiving the HPV vaccine.
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Conclusion
The HPV vaccine has the potential to further decrease the development of cervical
cancer. The CDC recommends that women up to the age of 26 receive the HPV vaccine.
Women ages 18-26 years may not have been exposed to the HPV vaccine recommendation as
adolescents; therefore, they may suffer disproportionately from cervical cancer in the future.
This analysis offers insight into some of the barriers college women may face in obtaining the
HPV vaccine. Race was a barrier to HPV vaccination in this analysis. Additionally, lack of
certain health behaviors (i.e. gynecological exam in the past 12 months and lacking a source of
health insurance) influenced HPV vaccination rates. Decreasing disparities in health care is
often a focus of public health. Acknowledging that minority women have lower HPV
vaccination rates and drawing attention to potential barriers, allows health policy makers to
formulate plans regarding future health promotion activities.
Adolescent girls are the primary focus when trying to increase HPV vaccination rates.
Nonetheless, women over the age of 18 may still benefit from decreased cervical cancer rates
provided by HPV vaccination. This analysis did not explore perceived risks, perceived benefits,
perceived severity or the HPV knowledge level of the respondents, which can influence a
woman’s choice to receive the vaccination.

Recommendations
1. Health promotion activities should be targeted to specific populations in an effort to
increase HPV vaccination rates.
2. Promote general preventative health behaviors such as yearly gynecological exams.
3. Encourage research regarding HPV vaccination recommendation patterns by physicians.
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4. Promotion of the HPV vaccine while women are seeking another form of preventative
health care could provide a window of opportunity to educate women about the vaccine
and potentially increase vaccination rates. (E.g. provide women with HPV vaccine
information at flu vaccine drives).

Timmerie Cohen
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